

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32



**The evolution and protective benefits of
immune responses in North American
house finches (*Haemorhous mexicanus*) to
*Mycoplasma gallisepticum***

Submitted by Daisy Gates to the University of Exeter as a
thesis for the degree of Masters by Research in Biological
Sciences, May 2018.

This thesis is available for Library use on the
understanding that it is copyright material and that no
quotation from the thesis may be published without proper
acknowledgement.

I certify that all material in this thesis which is not my own
work has been identified and that no material has
previously been submitted and approved for the award of
a degree by this or any other University.

33

34

Acknowledgements

35

36

I would like to thank my two supervisors on this project: Drs Camille

37

Bonneaud and Mario Recker, for their instruction and guidance, and for going

38

above and beyond to support me through the research process and my

39

personal professional development. They have been fantastic mentors and

40

have made my experience thoroughly rewarding and enjoyable. I am also

41

grateful to members of my research group, past and present: Luc Tardy, Josh

42

Lynton-Jenkins, Andrea Dowling, Karen Keegan and Jocelyn Tan; for their

43

advice and camaraderie has proven invaluable to me, and to Molly Staley,

44

who allowed me to stay with her and mentored me during a collaborative work

45

visit. Numerous other members of staff have been vital to the completion of

46

this work. This includes MD Sharma, Karen Moore and Paul O'Neill, who have

47

given up their time to aid my progression through mentoring me in techniques

48

for next-generation sequencing & analysis. Similarly, Suzanne Kay, Toby

49

Doyle, JJ Valetta and Kat Roberts have always been approachable and

50

helpful, walking me through laboratory techniques or providing advice on

51

statistics. To Drs Lena Wilfert and Andrew McGowan I am also grateful, for

52

they helped me to develop teaching skills during my postgraduate degree. I

53

would also like to extend my thanks to Lewis Campbell for his unwavering

54

support and advice, to Vicky Gates who shows constant interest in my

55

research and whose friendship I could not do without, and finally to Andy

56

Gates, whose hard-working attitude and generosity is a source of constant

57

inspiration for me.

58

59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84

Thesis Abstract

Pathogen spillover to novel hosts represents a huge selective event, and can result in rapid evolutionary changes in both the pathogen and the host. However, it is seldom possible to identify which specific host characteristics are under selection following emergence, nor understand the evolutionary repercussions of these changes. In the early 1990's, *Mycoplasma gallisepticum* emerged in North American house finches (*Haemorhous mexicanus*) following a jump from poultry. Previous studies monitoring disease spread and response to infection provided details of temporal and geographic patterns of host history of exposure, including evidence of the evolution of resistance in populations with a long history of exposure. In this thesis, I explore the specific host responses that were subject to selection following disease emergence in coevolved, relative to unexposed populations and evaluate how this led to the qualitative disease dynamics previously observed. In chapter one, I show that susceptibility to infection must be equal in both susceptible and resistant host genotypes in order for selection to occur, with mortality avoidance most likely driving the mode and tempo of rapid selection on resistance and virulence evolution observed in this system. In the second chapter, I find limited evidence for a protective benefit of a commonly measured immune component: systemic antibody, and show other important immune processes that are involved in host resistance, including an avoidance of immune manipulation. Findings presented here demonstrate the importance of the specific mechanism of host responses in determining evolutionary trajectories.

Contents

85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121

Tables and figures	5
Chapter 1: Thesis introduction	7-14
Chapter 2: <i>Quantitative host resistance drives the evolution of increased virulence in an emerging pathogen</i>	15-35
2.1 Abstract	16
2.2 Introduction	17-20
2.3 Methods	20-24
2.4 Results	24-31
2.5 Discussion	31-35
Chapter 3: <i>Protective benefits of the immune response to <i>M.gallisepticum</i></i>	36-61
3.1 Abstract	36
3.2 Introduction	38-42
3.3 Methods	42-49
3.4 Results	50-54
3.5 Discussion	55-61
Chapter 4: Thesis discussion	72-75
Bibliography	

Figures and tables

122

123

124

125

Chapter 2

126

127

Table 1. Model parameters, page 24.

128

129

130

Figure 1. Short-term dynamics of population level *M. gallisepticum* infection prevalence, page 25.

131

132

133

Figure 2. Model simulations of host and pathogen population dynamics, page 27.

134

135

136

Figure 3. Effect of relative susceptibility and mortality on selection of host resistance phenotype, page 29.

137

138

139

Figure 4. Effects of host resistance on pathogen virulence evolution, page 31.

140

141

Chapter 3

142

143

144

145

146

147

148

Figure 1. Systemic antibody (IgY) concentration in finches from coevolved, Alabama (blue) and unexposed, Arizona populations (red) at 14, 28 and 35 dpi. Populations differ significantly in their early IgY responses two weeks post inoculation, page 51.

149

150

151

152

Figure 2. Log fold difference in transcript expression, page 53.

153

154

155

Table 2. Differentially expressed transcripts between unexposed and coevolved finch populations, page 54.

156

157

Supplementary figures and tables

158

159

160

161 **Figure S1.** Flow diagram of the 2 strain - 2 phenotype SIR
162 model, page 62.

163

164 **Figure S2.** Seasonal variation in birth, death and disease
165 transmission, page 63.

166

167 **Figure S3.** Stratified prevalence of *M.gallisepticum.*, page
168 64.

169

170 **Figure S4.** The effects of the recovery rate on the
171 selection of host resistance and bacterial virulence, page
172 65.

173

174 **Figure S5:** The effect of relative susceptibility on the
175 selection of host resistance and bacterial virulence, page
176 66.

177

178 **Figure S6.** The effect of parasite clearance on the
179 selection of host resistance and bacterial virulence, page
180 67.

181

182 **Figure S7:** RSEM correlation matrix of sample similarity,
183 page 68.

184

185 **Table S1:** Differentially expressed transcripts between
186 Alabama and Arizona finches, pages 69-71.

187

188

189

190

191

192

193

Chapter 1: General Introduction

194

195

196

197 Infectious diseases are important selective agents in a range of species,
198 including humans (Karlsson *et al.*, 2014), and have had devastating effects on
199 biodiversity due to their contribution to recent species declines (Lips *et al.*,
200 2006; Pounds *et al.*, 2006). Interpreting the protective benefits of host
201 responses to infection is complex, particularly in scenarios where pathogens
202 are able to manipulate host responses and cause damage through
203 immunopathology. Furthermore, external or unrelated ecological factors
204 including, but not limited to: host condition (Cornet *et al.*, 2014), resource
205 availability (Pedersen & Greives, 2008) and climate (Atkinson *et al.*, 2014) can
206 all influence the strength and type of response elicited, due to physiological
207 and energetic trade offs with other biological processes (Hawley *et al.*, 2012;
208 Cheatsazan *et al.*, 2013).

209

210 An additional layer of complexity facing ecologists and evolutionary biologists
211 is that hosts and pathogens continually adapt to one another, on both spatial
212 and temporal scales (Lively & Dybdahl, 2000; Decaestecker *et al.*, 2007) and
213 therefore the immune response is a dynamic and responsive process. As all
214 organisms including humans, live in a constantly varying environment, it is
215 therefore important that we aim to understand as much as possible about the
216 ecological interactions of hosts and pathogens in the context of natural
217 populations (Pedersen & Babayan, 2011).

218

219 There is growing appreciation that understanding host defenses at the
220 immediate time of infection is crucial for understanding the evolutionary
221 trajectories of host resistance and pathogen evolution (Mackinnon & Read,
222 2004). This knowledge is useful not only in developing treatments (Gandon *et*
223 *al.*, 2001), but also for targeting strategies for preventative measures (Griffin &
224 Catlla, 2013). Specifically, the nature of host responses can have a direct
225 impacts on pathogen evolution, influencing strategies for both transmission
226 and the level of damage they cause (Gandon & Michalakis, 2000; de Roode
227 *et al.*, 2008). For example, theoretical models have suggested that different
228 host strategies including pathogen growth inhibition, infection avoidance, or
229 tolerance, can affect whether pathogens evolve increasing, or decreasing
230 virulence (Gandon & Michalakis, 2000; Restif & Koella, 2003; Miller *et al.*,
231 2005, 2006).

232

233 The overarching aim of this thesis is to explore how different host defense
234 strategies influence host and pathogen evolution in North American house
235 finches (*Heamorrhous mexicanus*), and the bacterial pathogen *Mycoplasma*
236 *gallisepticum*. The research herein utilizes a variety of techniques including
237 mathematical modeling to generate hypotheses about the underlying
238 evolutionary mechanisms and infection dynamics in this system, as well as
239 analysis of the protective benefits of immune measures using transcriptomics
240 and molecular methods. The consistent underlying feature throughout is the
241 comparison of two host populations; Eastern finches from Alabama who have
242 been exposed to *M.gallisepticum* for over 20 years, versus Western finches

243 from Tempe, Arizona, who have remained naïve to the disease (Staley et al.
244 2017, in press).

245

246 **The emergence of *M.gallisepticum* in North American house finches**

247 *M.gallisepticum* is a common pathogen of poultry (Avakiana & Leyb, 1993;
248 Gaunson *et al.*, 2000a). In 1994, a novel strain emerged in North American
249 house finches, first reported in Washington DC (Ley *et al.*, 1996; Fischer *et*
250 *al.*, 1997), before spreading rapidly in the Eastern and Northern range of the
251 species (Dhondt *et al.*, 2005). Infection in the house finch results in severe
252 conjunctivitis and a disease of the upper respiratory tract (Ley *et al.*, 1996),
253 resulting in extremely high mortality rates (Hochachka & Dhondt, 2000). In an
254 effort to monitor disease spread, André Dhondt and colleagues set up the
255 volunteer-based monitoring scheme, the House Finch Disease Survey
256 (HFDS) (Dhondt *et al.*, 2006).

257

258 By the early 2000s, *M.gallisepticum* had moved Westwards, first appearing in
259 those from Missoula, MT (Duckworth *et al.*, 2003) and later in Portland, OR
260 (Ley *et al.*, 2006). Western populations are native to the U.S, differing
261 genetically to Eastern populations with little known admixture (Hawley *et al.*,
262 2008). However the low density of Western house finches across the Great
263 Plains, coupled with the non-migratory behaviour of the Western populations
264 (Sauer *et al.*, 2012) meant that disease spread more slowly in these regions.
265 Once established in different populations, it began to vary seasonally in
266 prevalence on both local and regional scales (Hartup *et al.*, 1998; Altizer *et*
267 *al.*, 2004; Dhondt *et al.*, 2005) characterised by semi-annual peaks,

268 corresponding to seasonal host aggregation and breeding (Hosseini *et al.*,
269 2004).

270

271 **Pathology and immune responses to *M.gallisepticum***

272 As aforementioned, *M.gallisepticum* manifests itself as a severe conjunctivitis,
273 characterised by conjunctival edema and disease of the upper respiratory
274 tract (Kollias *et al.*, 2004). Other symptoms of infection include decreased
275 motor activity (Kollias *et al.*, 2004), mass loss (Bonneaud *et al.*, 2012a) and
276 an increase in body temperature (Hawley *et al.*, 2012). In experimental
277 infection studies, morbidity was high (100%;(Kollias *et al.*, 2004)), but
278 mortality varied from just 5% (Kollias *et al.*, 2004) to over 90% (Farmer *et al.*,
279 2002).

280

281 As *M.gallisepticum* is an economically important disease affecting poultry
282 (Stipkovits & Kempf, 1996), much of what we know about its pathogenicity
283 and the immune processes involved with infection are from experimental
284 infections of both virulent and attenuated strains of poultry MG in chickens
285 (Mohammed *et al.*, 2007). MG has the ability to misdirect some components
286 of the inflammatory response, such that epithelial membranes on respiratory
287 mucosa are disrupted, allowing increased adherence and multiplication in
288 these tissues (Gaunson *et al.*, 2006). The ability of Mycoplasmas to both
289 suppress and potentiate different aspects of host immunity makes it
290 challenging to determine which processes that are under host versus
291 pathogen control (Staley & Bonneaud, 2015).

292

293 One approach to teasing apart host versus pathogen control of immune
294 processes in house finches is to make use of the comparison between
295 unexposed Western and exposed Eastern populations. In an experimental
296 infection of finches from both populations in 2007, Bonneaud and colleagues
297 found that birds from exposed (Alabama) populations up-regulated genes
298 associated with immunity, relative to finches from unexposed populations
299 (Arizona) (Bonneaud *et al.*, 2011). Furthermore, birds from unexposed
300 populations down-regulated immune genes at two weeks post infection,
301 suggesting that unexposed birds were more susceptible to
302 immunosuppression, consistent with the evolution of resistance in Eastern
303 birds (Wang *et al.*, 2006; Bonneaud *et al.*, 2011).

304

305 In a later study, it was revealed that significant differences in splenic gene
306 expression between populations as early as 3dpi could be detected, indicating
307 that the spread of resistance involved a change in innate immune processes
308 (Bonneaud *et al.*, 2012b). Unexposed birds down-regulated genes associated
309 with immunity at 14dpi, but up-regulated complement-factor H gene, which is
310 known to constrain the activity of the complement cascade. However,
311 exposed birds were able to up-regulate genes involved with protective
312 immunity, such as CD74, which is associated with the assembly of MHC class
313 II associated molecules. Thus, it was concluded that gene expression patterns
314 were consistent with the hypothesis that some components of the immune
315 response were being suppressed in finches from Western populations, and
316 that birds from Eastern populations had enhanced protective immunity by
317 comparison (Bonneaud *et al.*, 2012b). However, in spite of an awareness of

318 some of the components of the house finch immune response to MG, their
319 protective benefits, as well as the conditions leading to rapid selection on host
320 resistance traits, remains to be elucidated.

321

322

323 **Thesis overview**

324 All of the work herein focuses on the exposed and unexposed populations
325 described above, aiming to examine the conditions that allowed for rapid host
326 evolution, and the functional significance of inter-population differences in
327 host immune response. Each chapter is written as a discrete manuscript, with
328 an abstract, introduction, methods, results and discussion.

329

330 **Chapter 2: Quantitative host resistance drives the evolution of increased** 331 **virulence in an emerging pathogen**

332 Emergent infectious diseases can have a devastating impact on host
333 populations and generate high selective pressures on both hosts and
334 pathogens. As a consequence, rapid adaptations in host resistance and
335 pathogen virulence are frequently observed following an initial severe
336 outbreak. However, it is often unclear to what extent hosts will evolve to
337 prevent infection (*qualitative resistance*) or limit its deleterious effects
338 (*quantitative resistance*) and what the evolutionary repercussions will be for
339 the pathogen. Previous studies on MG in house finches have indicated that
340 the evolution of host resistance occurred rapidly, within just a few generations
341 (Bonneaud *et al.*, 2011), accompanied by parallel patterns of increased
342 pathogen virulence (Hawley *et al.*, 2013). Using a two strain, two host SIR-

343 based evolutionary modelling approach, we investigate the dynamical
344 interplay between host resistance and pathogen virulence with a specific
345 emphasis on the likely resistance trait underlying the observed shift in host
346 phenotypes and evolution towards higher virulence.

347

348 **Chapter 3: Protective benefits of the immune response to**

349 ***M.gallisepticum***

350 Various studies have highlighted how a history of exposure to a pathogen can
351 result in adaptive changes in immune responses (Best & Kerr, 2000; Kerr &
352 McFadden, 2002). However, when pathogens have the ability to manipulate
353 host responses, it is often unclear as to whether specific components of
354 immunity are protective, or damaging (Sansonetti & Di Santo, 2007).
355 Furthermore, certain aspects of the host immune response are often assumed
356 to be protective, despite little evidence to suggest that they have a direct role
357 in pathogen control. Such is the case with circulating anti-*M.gallisepticum*
358 antibodies (IgY), for which no direct protective benefit has yet been found in
359 poultry (Noormohammadi *et al.*, 2002), and for which the benefit has not yet
360 been tested in house finches. Using measures of host pathology, host
361 condition, measures of antibody concentration and RNA-sequencing to
362 uncover differential gene expression, I examine the underlying differences in
363 the host response to *M.gallisepticum* infection between exposed and
364 unexposed populations in relation to the likelihood of recovery, pathogen
365 clearance and mortality. In doing so, I uncover how a history of pathogen
366 exposure has shaped the response to infection and provide precursory

367 evidence for how resistant hosts are able to avoid the damaging effects of
368 infection.

369

370 **Chapter 4: Discussion and future directions**

371 Finally, in chapter 4 I discuss my findings in the context of what is known
372 about host-pathogen evolution in house finches with MG, as well as the
373 potential wider implications of my research in relation to other emerging
374 infectious diseases. I conclude by suggesting some future directions in this
375 area.

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398 **Chapter 2: Quantitative host resistance drives the evolution of increased**
399 **virulence in an emerging pathogen**

400

401

402 Daisy E. Gates¹, Camille Bonneaud¹, Mario Recker^{2,*}

403

404 1. Biosciences, University of Exeter, Penryn, Cornwall, TR10 9FE, UK

405 2. Centre for Mathematics & the Environment, University of Exeter, Penryn,

406 Cornwall, TR10 9FE, UK

407 **Abstract**

408 Emergent infectious diseases can have a devastating impact on host
409 populations. The high selective pressures on both the hosts and the
410 pathogens frequently lead to rapid adaptations in host resistance and
411 pathogen virulence following an initial outbreak. However, it is often unclear
412 whether hosts will evolve to decrease infection-associated fitness costs
413 through a form of resistance that either prevents the establishment of infection
414 (*qualitative resistance*) or limits its deleterious effects, for e.g. through immune
415 functioning (*quantitative resistance*). Equally, the evolutionary repercussions
416 these resistance mechanisms have for the pathogen are largely unknown.
417 Here we take advantage of the well-documented outbreak of the highly
418 pathogenic bacteria *Mycoplasma gallisepticum* in North American house
419 finches. Using an evolutionary modelling approach, we investigate the
420 dynamical interplay between host resistance and pathogen virulence. With a
421 specific emphasis on the evolved resistance trait, we demonstrate that the
422 observed rapid shift in host phenotypes following the outbreak is suggestive of
423 strong selection pressure to reduce infection-associated mortality. This in turn
424 created the ecological conditions that selected for increased bacterial
425 virulence. Our results thus suggest that quantitative host resistance, which
426 inadvertently helps to maintain high levels of disease prevalence in the
427 population, is the key factor underlying the evolutionary interactions in this
428 natural host-pathogen system.

429

430 **Introduction**

431 Antagonistic interactions between hosts and pathogens can give rise to
432 intense selection pressures and trigger rapid evolutionary changes in both
433 (Buckling & Rainey, 2002; Paterson *et al.*, 2010). This is particularly true in
434 the context of novel disease outbreaks, in which potentially devastating
435 impacts on the host population are expected to feed back to the pathogen
436 through a rapidly changing host environment (Lively, 1989; Best & Kerr, 2000;
437 Paterson *et al.*, 2010). When faced with high infection-associated fitness
438 costs, hosts can evolve either to prevent the establishment of infection,
439 referred to as *qualitative resistance*, or limit its deleterious effects, referred to
440 as *quantitative resistance*, through immune function (Gandon & Michalakis,
441 2000; Sepil *et al.*, 2013). Quantitative resistance is a term used to describe a
442 scenario where by all hosts can become infected with a parasite, but resistant
443 hosts are harmed less through traits that reduce the performance of a parasite
444 in resistant hosts; differing to tolerance, which reduces the fitness costs of
445 infection (Koskela *et al.*, 2002). For example, quantitative resistance is
446 conferred through specific MHC-supertypes associated with a reduction of
447 parasitaemia (parasite load) in great reed warblers (*Acrocephalus*
448 *arundinaceus*) (Westerdahl *et al.*, 2012) and great tits (*Parus major*) (Sepil *et*
449 *al.*, 2013) infected with *Plasmodium* parasites. Evidence for the evolution of
450 different resistance strategies has been observed in many species; however,
451 whether hosts will evolve qualitative or quantitative resistance, particularly in
452 response to an emerging disease, remains largely unknown (Gandon &
453 Michalakis, 2000).

454 Due to the close ecological relationship between pathogens and their hosts,
455 the type of host evolutionary responses to infection is expected to impact
456 pathogen exploitation strategies and subsequent evolution of virulence (the
457 reduction to host fitness during infection) (Read, 1994; Roy *et al.*, 2000).
458 Previous theoretical studies that distinguish host responses to infection as
459 either preventing or limiting pathogen exploitation through reduced
460 susceptibility or immune function (resistance), or offsetting infection-
461 associated fitness costs (tolerance), have yielded useful predictions as to
462 when we might expect evolution towards a high or low virulence strategy (Roy
463 *et al.*, 2000; Miller *et al.*, 2006; Best *et al.*, 2014). However, we still lack a full
464 understanding of the consequences of different resistance mechanisms (i.e.,
465 qualitative *versus* quantitative) on the evolution of pathogen virulence,
466 particularly in wild populations with recurring epidemics. As certain resistance
467 alleles are expected to be advantageous only when the pathogen is present
468 (Westerdahl *et al.*, 2012), cycles of disease prevalence are likely to effect
469 host-pathogen evolutionary trajectories.

470 Pathogens are generally assumed to maximise their fitness (in terms of their
471 basic reproductive number, R_0) by optimising the trade-off between
472 transmission rate and infection duration. Therefore, optimal virulence is highly
473 dependent on these two factors. For example, a high proportion of
474 qualitatively resistant hosts in a population will decrease overall parasite
475 prevalence, which limits transmission opportunities and has thus been
476 predicted to select for lower virulence (Baalen, 1998; Gandon & Michalakis,
477 2000). On the other hand, quantitative resistance traits, which permit
478 infections but decrease infection duration, for example through immune

479 activation, are expected to select for higher virulence (Baalen, 1998; Gandon
480 & Michalakis, 2000; Gandon *et al.*, 2002). What these studies highlight is that
481 evolution of host resistance and pathogen virulence are intricately linked and
482 require further investigation.

483 The outbreak of the bacterium *Mycoplasma gallisepticum* in North American
484 house finches (*Heamorrhous mexicanus*) mid-1990s following a jump from
485 poultry provides us with a unique opportunity to disentangle the evolutionary
486 interplay between host resistance and pathogen virulence in a natural system.
487 The ensuing epizootic of severe conjunctivitis led to the death of millions of
488 house finches (Luttrell *et al.*, 1998; Hochachka & Dhondt, 2000; Kollias *et al.*,
489 2004; Dhondt *et al.*, 2005) and was followed by the rapid evolution of host
490 resistance, which spread from ~20% to ~80% within 12 years following the
491 outbreak (Bonneaud *et al.*, 2011; Adelman *et al.*, 2013). Experimental studies
492 showed that house finches from disease-exposed populations displayed lower
493 pathogen load following infection than finches from disease-unexposed
494 populations, as well as gene expression changes in immune-associated
495 tissue that were consistent with increased resistance to infection (Wang *et al.*,
496 2006; Bonneaud *et al.*, 2011, 2012b). The underlying mechanism of
497 resistance and whether it confers protection from infection establishment
498 and/or from infection-induced morbidity or mortality is still unknown, however.
499 Furthermore, parallel changes in bacterial virulence were also observed, with
500 virulence, estimated as the severity of clinical symptoms, increasing over the
501 course of the epizootic (Hawley *et al.*, 2013). If and how the spread of host
502 resistance contributed to increased virulence over time remains to be
503 established.

504 Here we used a modelling approach to investigate the consequences of
505 different types of host resistance on temporal changes in host evolution,
506 disease prevalence and pathogen virulence using the *M. gallisepticum* -
507 house finch disease system. Building on previous findings of rapid resistance
508 evolution in this system, this approach enabled us to test hypotheses
509 generated in previous theoretical studies (Gandon & Michalakis, 2000) to an
510 important and well-characterised avian system. We investigate the effects of
511 qualitative resistance traits that prevent infection versus quantitative
512 resistance traits that either limit disease severity and thus transmissibility or
513 simply reduce infection-associated mortality on resulting patterns of host
514 resistance and parasite virulence evolution. Our results suggest that the
515 observed spread of host resistance was the result of strong selection pressure
516 to reduce *M. gallisepticum* induced mortality, which in turn provided the
517 competitive advantage for more virulent bacteria.

518

519 **Methods**

520 In order to investigate the evolutionary dynamics of host resistance and
521 pathogen virulence, we developed a two-strain, two-phenotype *SIRS* model
522 with seasonal forcing. We divided the host population, N (which is not
523 assumed to remain constant), into two broad categories, resistant (N_r) and
524 non-resistant (N_{nr}) hosts, with resistant hosts assumed to carry a resistance
525 trait offering lower susceptibility to infection, faster infection clearance rate or
526 lower disease-associated mortality. Hosts can become infected with either a
527 high virulence strain (h) or a low virulence strain (l) of *M. gallisepticum* and

528 transmission is frequency dependent (proportional to S/N). For simplicity, we
529 assumed that upon recovery birds gain full but waning immunity against
530 reinfection and any differences in pathogen load that may occur between
531 resistant and non-resistant hosts does not affect their capacity to transmit.
532 Interactions between strains, such as partial cross-immunity or super-
533 infection, were not considered. The rate of change in the number of
534 *susceptible* ($S_{nr,r}$), *infected* ($I_{nr,r}^{h,l}$) and *recovered* birds ($R_{nr,r}$) was given by
535 the following set of differential equations:

$$\frac{dS_{nr}}{dt} = b(t)N_{nr} - \beta(t) \left((I_r^l + I_{nr}^l) + \lambda_1(I_r^h + I_{nr}^h) \right) \frac{S_{nr}}{N} + \delta R_{nr} - \mu(t)S_{nr}$$

$$\frac{dS_r}{dt} = b(t)N_r - \rho_1\beta(t) \left((I_r^l + I_{nr}^l) + \lambda_1(I_r^h + I_{nr}^h) \right) \frac{S_r}{N} + \delta R_r - \mu(t)S_r$$

$$\frac{dI_{nr}^l}{dt} = \beta(t)(I_r^l + I_{nr}^l) \frac{S_{nr}}{N} - \sigma I_{nr}^l - \zeta I_{nr}^l - \mu(t)I_{nr}^l$$

$$\frac{dI_{nr}^h}{dt} = \lambda_1\beta(t)(I_r^h + I_{nr}^h) \frac{S_{nr}}{N} - \lambda_2\sigma I_{nr}^h - \lambda_3\zeta I_{nr}^h - \mu(t)I_{nr}^h$$

$$\frac{dI_r^l}{dt} = \rho_1\beta(t)(I_r^l + I_{nr}^l) \frac{S_r}{N} - \rho_2\sigma I_r^l - \rho_3\zeta I_r^l - \mu(t)I_r^l$$

$$\frac{dI_r^h}{dt} = \rho_1\lambda_1\beta(t)(I_r^h + I_{nr}^h) \frac{S_r}{N} - \rho_2\lambda_2\sigma I_r^h - \rho_3\lambda_3\zeta I_r^h - \mu(t)I_r^h$$

$$\frac{dR_{nr}}{dt} = \sigma(I_{nr}^l + \lambda_2 I_{nr}^h) - \delta R_{nr} - \mu(t)R_{nr}$$

$$\frac{dR_r}{dt} = \rho_2\sigma(I_r^l + \lambda_2 I_r^h) - \delta R_r - \mu(t)R_r$$

536

537 where $b(t)$ is the seasonal birth rate, $\beta(t)$ is the seasonal transmission
538 coefficient, σ is the recovery rate, ζ is the disease-associated mortality rate,
539 and $\mu(t)$ is the natural and season-dependent death rate. Supplementary
540 Figure S1 illustrates this model as a flow diagram.

541 We used two sets of scaling factors to investigate the (independent) effect(s)
542 of host resistance (ρ_1, ρ_2, ρ_3) and pathogen virulence ($\lambda_1, \lambda_2, \lambda_3$). For example,
543 $\rho_2 (\geq 1)$ describes the relative increase in the recovery rate for birds of the
544 resistant phenotype, whereas $\lambda_1 (\geq 1)$ describes the relative increase in the
545 transmission rate of birds infected with the more virulent strain. Considering
546 host susceptibility, recovery rate and mortality rate independently allows us to
547 investigate the full spectrum of resistance, from purely *qualitative* ($\rho_1 <$
548 $1, \rho_2, \rho_3 = 1$, i.e. decrease susceptibility but equal infection length and
549 mortality rate) to purely *quantitative* ($\rho_1 = 1, \rho_2 \geq 1, \rho_3 \leq 1$, i.e. equal
550 susceptibility but either increase clearance and/or decreased mortality).

551 Seasonal changes in house finch demography and aggregation rates have
552 previously been shown to be important in generating semi-annual cycles of *M.*
553 *gallisepticum* prevalence (Altizer *et al.*, 2004; Hosseini *et al.*, 2004). We
554 therefore incorporated seasonality into our model by using time-dependent
555 birth, death and transmission rates (see Supplementary Figure S2). Birth
556 rates, $b(t)$, peak in July / August, whereas mortality, $\mu(t)$, is highest during
557 winter months (see Supplementary Figure S2). Driven by social aggregation
558 during the mating season and the formation of winter foraging flocks, we
559 assumed that transmission rates, $\beta(t)$, fluctuate semi-annually (Altizer *et al.*,

560 2004). The seasonal birth, mortality and transmission rates are given as
561 follows:

$$b(t) = b_0(\sin((t - 0.1)\pi))^{k_b}$$

$$\mu(t) = \mu_0(0.4 + 0.6 (\sin((t - 0.5)\pi))^{k_d})$$

$$\beta(t) = \beta_0(0.2 + 0.8 ((\sin((t - 0.35)\pi))^{k_t} + (\sin((t + 0.35)\pi))^{k_t}))$$

562 with b_0 , μ_0 and β_0 denoting the peak birth, death and transmission rates,
563 respectively. k_b , k_d and k_t are (even-valued) shape parameters that
564 determine the length of a season.

565 We initialised the model assuming a 20% background prevalence in host
566 resistance (in line with empirical observations;(Bonneaud *et al.*, 2011)) and
567 equal prevalence of high and low virulent strains of *M. gallisepticum*. Host
568 recovery rate was set at 2 months (Bonneaud, unpublished) and the loss of
569 immunity was set at 14 months (Kollias *et al.*, 2004). Table 1 provides a
570 summary of the model's parameters.

571

572

573

574

575

576

577

Table 1: Model Parameters.

Parameter	Description	Value	Range
σ	recovery rate (per year)	6	[5,10]
δ	rate of loss of immunity (per year)	0.9	[0.5,1.5]
ζ	disease associated death rate (per year)	3	[2,4]
k_t	shape parameter (transmission)	20	-
k_b	shape parameter (birth)	80	-
k_d	shape parameter (death)	10	-
β_0	max transmission coefficient	48	-
b_0	max birth rate (per year)	3.61	-
μ_0	max death rate (per year)	0.3	-
ρ_1	susceptibility scale factor (resistance)	1	[0,1]
ρ_2	recovery scale factor (resistance)	1	[1,2]
ρ_3	mortality scale factor (resistance)	0.1	[0,1]
λ_1	transmissibility scale factor (virulence)	1.2	[1,2]
λ_2	recovery scale factor (virulence)	1	[0,1]
λ_3	mortality scale factor (virulence)	2	[1,5]


579

580

581 **Results**582 **(a) General model behaviour assuming quantitative resistance**

583 First, we simulated our model considering all hosts as equally susceptible to
584 becoming infected, but with resistant and non-resistant hosts differing in their
585 infection-induced mortality rates. As shown in Figure 1, this model captured
586 the observed qualitative dynamics in disease prevalence over time, with the

587 two distinct peaks in spring and autumn corresponding to seasonal increases
 588 in host population densities and aggregation, and hence in transmission
 589 opportunities (Hosseini *et al.*, 2004).



590


591 **Figure 1. Short-term dynamics of population level *M. gallisepticum***
 592 **infection prevalence.** (a) Seasonal component of Empirical prevalence data
 593 adapted from (Altizer *et al.*, 2004; Hosseini *et al.*, 2004). Red line represents
 594 Southern regions of the Eastern United states, blue line represents central
 595 regions and green line represents northern regions. (b) Model simulation
 596 capturing the semi-annual dynamics driven by seasonal fluctuations in host
 597 densities and aggregation rates. Parameter values: $\rho_1 = 1, \rho_2 = 1, \rho_3 =$
 598 $0.1, \lambda_3 = 2$; other parameter values as in Table 1.

599

600 Following the initial outbreak, we found that the number of susceptible hosts
 601 and the total host population size decreased significantly as a direct result of

602 high infection-associated mortality rates (Figure 2a). This decrease in the
603 number of susceptible hosts then led to a substantial decline in disease
604 prevalence (Figure 2b). When we stratified the host population into resistant
605 and non-resistant phenotypes (Figure 2c), our model revealed rapid
606 phenotypic changes in the host population in line with previous empirical
607 studies (Bonneaud *et al.*, 2011), with resistant hosts reaching ~80%
608 prevalence after around ten years post-emergence. In parallel, while the low
609 virulence pathogen strain dominated during the initial phase of the epizootic, it
610 became outcompeted by the more virulent strain after around 8 years (Figure
611 2b and d). These results therefore suggest that strong pathogen-induced
612 selection pressure and the subsequent increase in resistant host phenotypes
613 in the population created the conditions for a more virulent pathogen strain to
614 emerge and dominate (Figure 2d, S3).

615



616

617 **Figure 2. Model simulations of host and pathogen population dynamics.**
 618 (a) Following disease emergence there is a significant decrease in the
 619 number of susceptible hosts (solid line) and total host population size (dashed
 620 line). (b) Number of individuals infected with the low virulence (solid line) and
 621 high virulence strain (dashed line) over time showing initial dominance of the
 622 low virulent strain, which eventually gets outcompeted. (c) Change in the
 623 proportion of the host population with a non-resistant or resistant phenotype
 624 (N_{nr} and N_r , respectively). (d) Proportion of host population infected with low
 625 or high virulence strains over time showing an initial expansion of the low
 626 virulence strain until the number of resistant hosts has reached a critical
 627 threshold that tips the balance in favour of the more virulent strain. Parameter
 628 values: $\rho_1 = 1, \rho_2 = 1, \rho_3 = 0.1, \lambda_3 = 2$; other parameter values as in Table 1.

629

630 Similar model behaviour was obtained when assuming quantitative resistance
 631 as an increase in recovery rate, which equally selected for host resistance in
 632 the population, albeit at a much-reduced rate (Supplementary Figure S4).
 633 What these results suggest is that disease prevalence needs to be maintained
 634 at a sufficiently high level for the fast and continued selection of host
 635 resistance traits. That is, both a reduction in susceptibility and a reduction in


636 the infectious periods drastically reduce the number of susceptible hosts and
637 hence disease transmission, which consequently lowers the selection
638 pressure in the population.

639

640 **(b) Qualitative resistance reduces the speed of phenotypic change**

641 We next tested the effects of different resistance strategies on the host's
642 evolutionary response to infection. As shown in Figure 2c and 3a (top graph),
643 quantitative resistance in the form of a reduction in disease-associated
644 mortality causes a rapid change in host phenotype distribution, with resistant
645 birds increasing in frequency from ~20% to ~80% in just ten years in line with
646 empirical observations. Instead, when modelling resistance as a difference in
647 susceptibility to becoming infected, we found a marked reduction in the speed
648 of resistance evolution, with resistant hosts only making up about half of the
649 population ten years after disease emergence (Figure 3a, bottom graph).
650 Running a sensitivity analysis over these two resistance traits (relative
651 susceptibility, ρ_1 , and relative mortality, ρ_3) confirmed that resistant birds need
652 to have similar rates of infection, but a much reduced risk of mortality from
653 disease related causes, in order to explain the observed shift in host
654 phenotypes (Figure 3b).

655



656

657 **Figure 3. Effect of relative susceptibility and mortality on selection of**
 658 **host resistance phenotype.** (a) Model output for the frequency of resistant
 659 (solid line) versus non-resistant (dashed line) host phenotypes over time.
 660 Reduction of infection-associated mortality leads to the rapid selection of
 661 resistant phenotypes (HR, top graph), whereas a reduction of susceptibility to
 662 infection slows down the selection for resistance (LR, bottom graph). (b) The
 663 effect of relative mortality and relative susceptibility of resistant birds on the
 664 prevalence of the resistant phenotype at ten years post emergence. Low
 665 frequencies of resistant phenotypes occur when mortality is similar between
 666 the two host phenotypes and when resistant hosts are significantly less
 667 susceptible to infection (LR). High levels of population-level resistance occur
 668 when resistant and non-resistant hosts are equally likely to become infected
 669 but experience significantly lower mortality (HR). Parameter values: $\rho_2 =$
 670 $1, \lambda_3 = 2$; other parameter values as in Table 1, except in (a): $\rho_1 = 0.9, \rho_3 =$
 671 0.1 (top) and $\rho_1 = 0.1, \rho_3 = 0.9$ (bottom).


672

673 (c) Host resistance and its effect on virulence evolution

674 Finally, we considered the selective impact of host resistance on the evolution
 675 of pathogen virulence. As demonstrated above (Figure 2b and d) and in line
 676 with empirical observations, assuming quantitative resistance as a decrease
 677 in mortality can cause the selection of more virulent bacteria over time.
 678 However, the exact conditions that favour a more virulent strain crucially
 679 depend on its mortality rate relative to that of a less virulent strain, λ_3 and the
 680 extent to which infection-induced mortality is reduced in resistant hosts, ρ_3 . To

681 demonstrate this we ran a sensitive analysis over these two scaling factors
682 (λ_3 and ρ_3) and recorded the relative frequency of both strains over time
683 (Figure 4). As shown in Figure 4a, under the assumption that disease-
684 associated mortality is much higher for the more virulent strain, selection will
685 favour the less virulent strain as the gain in transmissibility is outweighed by
686 the rapid loss of infected hosts. On the other hand, if the mortality rates from
687 infection with either strain are not too dissimilar and resistant hosts are
688 significantly more protected against infection-induced mortality, more virulent
689 bacteria will have the fitness advantage.

690 Crucially, whilst the other two resistance strategies (reduced susceptibility or
691 reduced infection length through faster recovery) can also select for increased
692 virulence (Supplementary Figures S5 and S6, respectively), the conditions
693 under which this may take place are such that either the disease and/or host
694 population goes extinct, or the rate of change in host phenotype distribution is
695 too slow to be compatible with the data. Taken together, our results thus
696 suggest that quantitative resistance, which offers the host protection against
697 disease associated mortality, was the most likely factor underlying the
698 observed co-evolutionary dynamics in this wildlife disease system.



699

700 **Figure 4. Effects of host resistance on pathogen virulence evolution.** (a)
 701 Model output showing the number of birds infected with the low (blue) and
 702 high (red lines) virulence strain of *M. gallisepticum*. When resistant and non-
 703 resistant host phenotypes experience the same levels of infection-associated
 704 mortality the more virulent strain will go extinct (top graph), whereas greatly
 705 reduced infection associated death rates in resistant hosts can provide a
 706 fitness advantage for more virulent bacteria (bottom graph). (b) The effect of
 707 relative mortality caused by the high virulence strain versus the relative
 708 mortality in resistant hosts on the evolution of virulence, determined as the
 709 frequency of the high virulent strain at ten years post emergence. Parameter
 710 values: $\rho_1 = 1, \rho_2 = 1$; other parameter values as in Table 1 as in Table 1,
 711 except in (a): $\lambda_3 = 3, \rho_3 = 0.5$ (top) and $\lambda_3 = 2, \rho_3 = 0.1$ (bottom).

712

713 Discussion

714 In the present study, we identified the set of conditions that could explain the
 715 rapid selection of host resistance and parallel increased pathogen virulence
 716 following the epizootic outbreak of *M. gallisepticum* in North American house
 717 finches. Specifically, we have demonstrated that neither a reduction in host
 718 susceptibility to *M. gallisepticum* infections, nor an increase in parasite
 719 clearance rates, is compatible with the empirical data. Indeed, the impact of
 720 each on infection prevalence would cause a reduction in disease-induced
 721 selection pressure to the extent that we would no longer be able to observe
 722 shifts in both host and pathogen phenotypes. Instead, our results suggest that

723 the rapid, disease-induced selection of host resistance traits based on
724 reducing infection-associated mortality, for instance through a lowering of
725 pathogen load, was the key driver for the subsequent increase in bacterial
726 virulence in this important host-pathogen system.

727 Our results are in line with both empirical observations and theoretical
728 predictions. Experimental work on the evolution of resistance in house finches
729 has shown that resistance spread rapidly from standing genetic variation in
730 less than 12 years of disease exposure (Farmer *et al.*, 2005; Hawley *et al.*,
731 2007; Bonneaud *et al.*, 2011). This speed of host adaptation suggests that the
732 disease must have imposed a strong selection pressure on the host
733 population, a hypothesis further supported by the high rates of mortality
734 observed in the wild following outbreak (Hochachka & Dhondt, 2000). In
735 accordance, our modelling study demonstrates that for a phenotypic change
736 to occur in the host population, house finches must incur a high fitness cost
737 from being infected with *M. gallisepticum*, with non-resistant finches paying a
738 higher cost than resistant ones.

739 The results of our model would suggest that resistant finches not only
740 experience reduced mortality when infected, but that they should also display
741 a level of susceptibility to infection similar to that of non-resistant birds. When
742 host resistance is modelled as reduced susceptibility to infection, its negative
743 impact on population-level infection prevalence is indeed too great to maintain
744 the selection pressure that would account for the rapid change in host
745 phenotype frequencies. A similar outcome was obtained when modelling
746 resistance as increased recovery rate: selection pressure on host resistance

747 subsequently dropped, thereby slowing down the speed of host phenotypic
748 change. The most likely resistance trait under selection in this system
749 therefore consists of a reduction in infection severity, which is compatible with
750 the notion of quantitative resistance.

751 It has previously been proposed that qualitative resistance, which lowers a
752 host's susceptibility to infection, should select for decreased pathogen
753 virulence and that this effect should positively increase with the proportion of
754 resistant individuals in the host population (Gandon & Michalakis, 2000).
755 Although we also found some conditions under which reduced susceptibility
756 could lead to an increase in virulence, the parameter regions where this
757 occurred resulted in model behaviours that are incompatible with the
758 observed data, leading either to (host or pathogen) population extinction or to
759 a reduction in selection pressure precluding major shifts in host phenotype
760 frequencies.

761 A number of studies to date have focussed on characterising the immune
762 response of wild populations to emerging infectious diseases (Kerr &
763 McFadden, 2002; Gregory *et al.*, 2005; Bonneaud *et al.*, 2012b). The
764 canonical example of the parallel evolution of host resistance and pathogen
765 virulence following disease emergence is the eradication attempt of European
766 rabbits (*Oryctolagus cuniculus*) of Australia using the *Myxoma* virus. Following
767 the release of highly virulent strains in 1950, which resulted in a dramatic
768 decline of the rabbit population by over 99% (Marshall *et al.*, 1955), virulence
769 was found to decrease and resistance via enhanced innate immunity to
770 spread in the host population (Best & Kerr, 2000). Although these findings

771 suggest that quantitative resistance may have driven the evolution of
772 resistance in this case, genes underlying both qualitative and quantitative
773 forms of resistance can be found in the wild, suggesting a role of both in
774 shaping host-pathogen interactions and coevolution. For example, a study on
775 wild great tits showed that different super types of the same MHC gene can
776 confer either qualitative or quantitative resistance to avian malaria (Sepil *et*
777 *al.*, 2013). Determining which form of resistance is under selection will shed
778 light on the phenotypic change expected in the host population, as well as on
779 the pathogen's evolutionary trajectory (Gandon & Michalakis, 2000).

780 An important aspect influencing the long-term evolutionary outcome of host-
781 pathogen interactions are the costs associated with either form of resistance.
782 It has been proposed that resistance through protective immunity is expected
783 to evolve only when the cost of mounting the immune response is lower than
784 the cost of being infected (Antonovics & Thrall, 1994; Boots & Bowers, 2004;
785 Viney *et al.*, 2005). House finches from populations that evolved resistance
786 have previously been found to lose more body mass following experimental
787 infections with *M. gallisepticum* than finches from unexposed populations
788 (Bonneaud *et al.*, 2012a). The fact that resistance has spread despite this
789 indicates that the fitness benefit of resisting either infection or infection-
790 associated morbidity ultimately outweighs the shorter-term energetic cost of
791 resistance. Hence, while our model does not include costs associated with
792 resistance, we do not expect such costs to impact the results of this study
793 other than by influencing the probability that resistance will go to fixation and
794 that resistant phenotypes will decline in frequency once the disease goes
795 extinct.

796 In conclusion, our results reiterate the important influence that the
797 mechanisms underlying host resistance can have on the mode and tempo of
798 host phenotypic change and pathogen virulence evolution. Distinguishing
799 between different forms of resistance in plants is common-place (Ewing *et al.*,
800 2000; Ramalingam *et al.*, 2003; Hein *et al.*, 2009), but has only scarcely been
801 applied to animal or human disease systems despite its importance for public
802 health. That is, many disease intervention measures that either prevent
803 infections (e.g. vaccination) or enhance clearance (e.g. drug treatment) will
804 effectively induce, or mimic, host resistance. Given the varying impacts of
805 different forms of resistance on the evolution of pathogen virulence,
806 inappropriate control measures can on occasion, result in undesirable
807 outcomes, such as increases in pathogen virulence (Gandon *et al.*, 2001) and
808 disease severity (Stevens *et al.*, 2007). Our study thus highlights the need for
809 a more detailed investigation of the evolutionary host-pathogen interactions in
810 order to minimise adverse effects of disease control.

811 **Chapter 3:Protective benefits of the immune response to**

812 ***M.gallisepticum***

813

814 Daisy E. Gates¹, Mathieu Giraudeau^{1,2}, M. D. Sharma, Molly Staley^{3‡}, Luc
815 Tardy¹, Karen Moore⁴, Geoffrey E. Hill³, Kevin J. McGraw² and Camille
816 Bonneaud¹

817

818 ¹*Biosciences, University of Exeter, Penryn, Cornwall TR10 9FE, UK*

819 ²*School of Life Sciences, Arizona State University, Tempe, Arizona 85287-*
820 *4501, USA*

821 ³*Department Biological Science, Auburn University, Auburn, Alabama 36849-*
822 *5414, USA*

823 ⁴Exeter Sequencing Service and Computational core facilities, Biosciences,
824 *University of Exeter, Exeter, Devon, UK*

825 [‡]*current address: Chicago Zoological Society, Brookfield, IL 60513, USA*

826

827

828

829

830

831

832

833

834

835

836 **Abstract**

837 The adaptive significance of immune components is now high priority on the
838 research agenda of many ecologists and evolutionary biologists, because
839 defining individual levels of host resistance is impossible without knowledge of
840 the efficacy of immune measures in combating infection. Protective effects of
841 immune measures are often assumed, although the extent to which they
842 confer protection likely depends on the history of pathogen exposure, as well
843 as the specific way in which the pathogen causes damage. Using RNA-seq
844 based transcriptomics, we assessed differential expression of immune and
845 immune associated genes between finches originating from unexposed and
846 coevolved house finch populations to infection. In addition, we assess the
847 efficacy of an easily measured immune component, systemic antibody (IgY) in
848 protection from mortality, symptom severity and the likelihood of increased
849 recovery or pathogen clearance. Stark inter-population differences in
850 transcriptional profiles are demonstrated, consistent with exposed populations
851 exhibiting an enhanced ability to avoid immune-pathological effects of
852 infection. In addition, we find significantly higher IgY concentration in exposed,
853 relative to unexposed, finch populations. However, we find no protective
854 benefit to increased circulating IgY concentrations, suggesting the increased
855 humoral response may be a by-product of the up-regulation of another
856 immune component.

857

858

859

860

861 **Introduction**

862 Infectious diseases exert profound selection pressure on their hosts;
863 influencing many aspects of host biology from reproductive modes (Liersch &
864 Schmid-Hempel, 1998) to behaviour (Berdoy *et al.*, 2000). Response to
865 pathogen exposure includes a suite of combative defense mechanisms, which
866 together make up the immune response. Evidence for the rapid evolution of
867 these responses in wild populations is growing; from rabbits with *Myxoma*
868 virus (Kerr & McFadden, 2002) to amphibians with chytridiomycosis (Savage
869 & Zamudio, 2016). Formerly the exclusive domain of immunologists, the study
870 of the adaptive significance of immune responses has become a high priority
871 on the research agenda of many evolutionary ecologists, because the costs
872 and benefits of the type and strength of response elicited strongly influence
873 the fitness of the host (Sheldon & Verhulst, 1996). In spite of this, the
874 characterization of immune responses of wild populations to emerging
875 diseases is rare, largely due to a scarcity of techniques available to do so,
876 particularly in non-model organisms.

877

878 One method for overcoming the lack of availability of reference genomes in
879 non-model organisms is to use RNA-seq based transcriptomics (Grabherr *et*
880 *al.*, 2013). However, this has scarcely been applied to wild systems, largely
881 due to the inability to control conditions in wild populations and due to the
882 potential for environmental contamination. However, this method is increasing
883 in popularity in a range of taxa from birds (Videvall *et al.*, 2015) to amphibians
884 (Campbell *et al.*, 2018). As hosts live in naturally varying environments, the
885 extrapolation of laboratory results to wild populations is often tenuous or not

886 completely suitable (Pedersen & Babayan, 2011). Never the less, in spite of
887 new techniques that are now available to characterize immune responses, it is
888 often unclear as to whether individual immune measures are protective, or if
889 they reflect individual levels of host resistance.

890

891 Often, antibody levels are used as a proxy for resistance in wild animals, due
892 to the tractability of taking fecal or hematological samples in the field.
893 Antibodies (also called Immunoglobulins), are produced by B lymphocytes in
894 response to specific antigens (Janeway *et al.*, 2001) and act to control
895 invading pathogens through various mechanisms, including neutralization
896 (Mazanec *et al.*, 1992; Palladino *et al.*, 1995; Teoh *et al.*, 2012), prevention of
897 adherence (Wallace *et al.*, 1991) or the activation of the complement cascade
898 (Diebolder *et al.*, 2014). However, whilst the humoral response is expected to
899 be protective, evidence suggests that antibodies may not always be effective
900 against certain pathogens (Amorim *et al.*, 2016; Dumke & Jacobs, 2016), or
901 that high antibody titres can be associated with more severe symptoms (Wells
902 *et al.*, 2014). In many cases, it is also unclear to what extent levels of antibody
903 correlate with levels of host resistance.

904

905 When diseases emerge in a novel host, it is possible to document how
906 coevolutionary history of exposure changes the mechanisms by which hosts
907 overcome infection. One such system is the bacterial pathogen *Mycoplasma*
908 *gallisepticum* in North American house finches (*Haemorhous mexicanus*). A
909 common pathogen of poultry, it emerged in Eastern finch populations in 1994
910 (Ley *et al.*, 1996). In house finches, *M.gallisepticum* causes conjunctivitis and

911 a disease of the upper respiratory tract. When the pathogen first emerged in
912 finches, it resulted in the deaths of millions of birds (Hochachka & Dhondt,
913 2000). By the early 2000s, *M.gallisepticum* had spread to Western finch
914 populations, although epidemic spread was slowed over the Great Plains due
915 to relatively low house finch densities (Sauer *et al.*, 2012). In fact, some
916 populations, such as finches in Tempe, Arizona remain unexposed to this day
917 (Staley *et al.* 2017, in press). Changes to the dynamics of *M.gallisepticum*
918 prevalence in Eastern house finch populations to endemic levels has been
919 attributed in part to the rapid spread of host resistance, occurring within just
920 12 years (Bonneaud *et al.*, 2011, 2012b).

921

922 Much of what is known about the immune response to *M.gallisepticum* is from
923 the poultry literature. *M.gallisepticum* infection is associated with suppressing
924 certain aspects of immunity (Mohammed *et al.*, 2007) including T-cell activity
925 2 weeks post inoculation (Ganapathy & Bradbury, 2003), and has been shown
926 to induce inflammatory responses, thus increasing number of tissue lesions
927 (Ley, 2008). During the early stages of the epizootic in house finches, Eastern
928 birds from Alabama displayed transcriptional responses to infection that were
929 similar to those from unexposed, Western finches from Arizona. However, in
930 the years following, Eastern birds began to differ in their responses. Previous
931 studies have demonstrated that these individuals were able up-regulate genes
932 involved in innate and acquired immunity, and harbored lower conjunctival
933 pathogen loads (Bonneaud *et al.*, 2011, 2012b). These results indicated that
934 differences in transcriptional response between populations did not simply
935 arise through ecological differences, but rather accompanied the evolution of

936 resistance. However, the efficacy of innate and acquired immune responses
937 in conferring survival and recovery still remain to be elucidated.

938

939 To examine the efficacy of innate and acquired responses in fighting
940 *M.gallisepticum* infection, we conducted an experimental infection and
941 examined systemic antibody (IgY) concentrations in relation to recovery from
942 symptoms (measured by eye-lesion severity), pathogen clearance (measured
943 by PCR-detection of the pathogen) and mortality. Although local antibody
944 concentration has been previously shown to have a role in mediating the
945 control of *M.gallisepticum* infection in chickens (Gaunson *et al.*, 2006), no
946 such protective role of local or circulating antibodies has yet been established
947 in house finches. We next examined whole-blood gene expression profiles, as
948 blood has recently been shown to be a useful tissue in detecting immune
949 stimulation in passerine birds (Meitern *et al.*, 2014). By comparing birds from
950 Eastern (Alabama) and Western (Arizona) populations, we investigate how a
951 history of disease exposure has shaped the response to infection in Eastern
952 birds.

953

954 We make several broad predictions with regards to population differences in
955 immune response, and the potential protective benefits. First, our results
956 would suggest a potential, protective benefit of circulating antibodies if: i)
957 antibody concentration is significantly higher in finches originating from
958 Alabama at one or all of the time points measured (if this occurs at a time
959 point early-on in infection, this may be suggestive of an enhanced speed of
960 antibody production), or ii) increased antibody responses are associated with

961 decreased mortality, increased recovery from symptoms or increased
962 pathogen clearance. Furthermore, if differences in transcriptional profiles
963 between populations show finches from Alabama decreasing the inflammatory
964 response, or up-regulating genes associated with adaptive immunity, this will
965 suggest that avoidance of immune-manipulation by *M.gallisepticum* has
966 played a role in the evolution of host resistance.

967

968 **Methods**

969 During the summer of 2015, wild house finches were captured from
970 populations with no prior exposure to *M. gallisepticum* in Arizona (N=25; 13
971 males and 12 females) and from populations that have been exposed to
972 *M.gallisepticum* since disease outbreak in Alabama (N=25; 12 males and 13
973 females) (Bonneaud et al submitted). Upon capture, lack of past and current
974 infection was verified using serum plate agglutination assay (Luttrell *et al.*,
975 1996) and PCR amplification of *M.gallisepticum* DNA in choanal swabs
976 (Luttrell *et al.*, 1996; Roberts *et al.*, 2001). All birds were brought back to
977 aviaries at Arizona State University, where they were housed for the
978 remainder of the experiment.

979

980 Finches were infected with *M.gallisepticum* isolates from 2007 (N=16), 2011
981 (N=16) and 2015 (N=18), with each isolate inoculated into 1 finch from
982 Alabama and 1 finch from Arizona (Bonneaud et al submitted). Development
983 of clinical symptoms was monitored by visually scoring eye lesion severity at
984 both eyes (0–5 scale; (Kollias *et al.*, 2004)) at 3, 6, 8, 14, 21, 25, 28 and 34
985 days post-infection (dpi). Peak symptom severity was determined as the

986 maximum score reached over the course of the experiment. Birds that
987 developed clinical symptoms of less than 4 (see below for rationale) and then
988 returned to a symptom score of 0 during the course of the experiment were
989 classified as having recovered.

990

991 Clearance of *M. gallisepticum* was determined from conjunctival and tracheal
992 swabs taken at 8, 14, 21 and 28 dpi and stored in 600 µL of RNA^{later}®
993 (ThermoFisher Scientific) at -80°C; DNA was extracted from the swabs using
994 Qiagen DNeasy Blood and Tissue kit (Tardy et al in prep). Amplification of *M.*
995 *gallisepticum* DNA was performed on the DNA extracts from all swabs using
996 *mgc2* primers developed by (García *et al.*, 2005). Birds were categorized as
997 having cleared the infection if the swabs became negative during the
998 experiment.

999

1000 At 14dpi, ~250 µL of whole blood was taken by brachial venipuncture. An
1001 aliquot of blood was directly stored in Tempus™ Blood RNA tubes
1002 (ThermoFisher Scientific, Leicester, UK) at -80°C for subsequent RNA
1003 extraction. We isolated serum from a second aliquot for ELISA through
1004 centrifugation at 2000XG for 15 minutes at 4°C; serum was stored at -80°C.

1005

1006 Host mortality was estimated based on the development of symptoms of
1007 scores 4 or 5, as these would lead to blindness-associated death in the wild
1008 (Bonneaud et al submitted). Therefore, when individuals reached peak
1009 symptoms of scores 4-5, this was described as a mortality event. The
1010 experiment was stopped at 35 dpi and all birds were euthanized as stipulated

1011 by home office licensing. Protocols were approved by Institutional Animal
1012 Care and Use Committees (IACUC) of Auburn University (permit # PRN 2015-
1013 2721) and of Arizona State University (permit #15-1438R), and by Institutional
1014 Biological Use Authorizations to Auburn University (# BUA 500).

1015

1016 **ELISA**

1017 Goat Polyclonal Passerine IgY-heavy and light chain Antibody (Bethyl
1018 laboratories, Inc, TX, USA) was diluted to 1:1000 dilution according to
1019 manufacturer protocol. The prepared antibody was then conjugated to a
1020 visible proprietary HRP (horse radish peroxidase) ligand for visualization in
1021 enzyme-linked immunosorbent assay (ELISA), according to instructions
1022 accompanying the Lighting-Link® HRP Conjugation Kit (Innova biosciences,
1023 Cambridge, UK) for an antibody: HRP molar ratio of 1:4.

1024

1025 *M.gallisepticum* specific antibody detection was performed with ELISA, with
1026 methods adapted from (Fassbinder-Orth *et al.*, 2016). Finch serum samples
1027 were diluted to 1:2400 in 1X sample conjugate diluent (Affinitech LTD, AR,
1028 USA) and 100 µL of each sample was added to plate microwells bound with
1029 inactivated *M.gallisepticum* antigen (Affinitech LTD). A standard curve of
1030 pooled sample was run on each plate in a 2-fold dilution series from 1:200-
1031 1:6400. Samples were run in duplicate, and care was taken to ensure that
1032 duplicates were distant from one-another to reduce variation caused by
1033 evaporation and edge effects. Plates were washed three times in 1X wash
1034 buffer (Bethyl laboratories, Inc), before adding 100 µL of the prepared HRP-
1035 conjugated Passerine IgY-heavy and light chain antibody, diluted to a

1036 1:10,000 concentration with sample conjugant diluent (Bethyl laboratories,
1037 Inc). After incubation for one hour in darkness, the plate was washed three
1038 times and 100 µL of TMB one component HRP microwell substrate (Bethyl
1039 laboratories, Inc) was added to each well and incubated for 15 minutes in
1040 darkness. The reaction was stopped with 100 µL of 0.18M H₂SO₄ and the
1041 plate was read on a plate reader at 450nm within 30 minutes of stopping the
1042 reaction.

1043

1044 **RNA isolation, cDNA library preparation and sequencing**

1045 Total RNA for ten birds infected with 2015 isolates of *M.gallisepticum* was
1046 extracted by a guanidinium thiocyanate-phenol-chloroform method using
1047 TRIzol® (Life Technologies, CA, USA). 100 µL of each whole blood sample
1048 was lysed and homogenized in 1ml of TRIzol® by a 20 second bead ruptor
1049 with silicone beads, before continuing with the standard TRIzol® protocol.
1050 RNA was subsequently purified using the RNeasy Micro-Kit (Qiagen),
1051 according to the manufacturer protocol, including DNase treatment and
1052 subsequent spin-column clean-up. The quality and RNA concentrations of
1053 each sample were determined by nano-drop (Thermofisher scientific),
1054 followed by Qubit (Life Technologies). Final RNA concentrations of samples
1055 were measured on a Bioanalyzer (Agilent, Manchester, UK), and checked for
1056 an RNA integrity number (RIN) of >8.

1057 After quality and quantity checks, library preparation and sequencing was
1058 performed by Exeter University sequencing service. The libraries were
1059 prepared from 500ng total RNA using the TruSeq stranded mRNA sample
1060 preparation kit (Illumina Inc, Essex, UK) including poly-A selection.

1061 Transcriptome sequencing was performed on the Illumina HiSeq2500
1062 platform, using a 125 base pairs sequencing run generating 458.5 million
1063 paired-end reads.

1064

1065 ***De novo* transcriptome assembly**

1066 Raw read quality was determined using FastQC software v0.11.6
1067 (<https://www.bioinformatics.babraham.ac.uk/projects/download.html#fastqc>).

1068 Adapters from each sample were removed individually using TrimGalore!
1069 v0.4.4, which removed poor-quality reads from the 3' end of the sequences
1070 and subsequently looked for and removed the standard Illumina adapters
1071 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). The

1072 trimmed reads across all ten samples were then combined into a single
1073 database. Trinity v2.5.1 was run in strand specific (RF) mode to generate
1074 three assemblies, of which the best was selected through computing the N50
1075 length statistics and proportion of reads mapping to the assembly (Honaas *et*
1076 *al.*, 2016).

1077

1078 **Transcript abundance estimation and gene expression analysis**

1079 Results of the *de novo* transcriptome assembly were used to perform
1080 expression analysis for each sample, due to the lack of a fully assembled
1081 *H.mexicanus* reference genome. Tools embedded in the Trinity differential
1082 expression module were used to do so, including Bowtie2 for mapping reads
1083 against the reference transcriptome and abundance estimation calculation
1084 using RSEM. Differential expression levels between unexposed (Arizona) and
1085 adapted (Alabama) were determined using the RSEM read counts matrix,

1086 alongside the Bioconductor edgeR package. Only the isoforms represented
1087 with at least a four-fold change and an adjusted P-value (FDR) of 0.01 were
1088 considered as differentially expressed in the comparison between individuals
1089 from Eastern and Western populations.

1090

1091 **Functional annotation of the transcriptome**

1092 The functional annotation of each predicted differentially expressed protein-
1093 coding sequence was performed with a search against the nonredundant
1094 (NR) database on NCBI using BLAST (<http://www.blast2go.com>) with an *E*-
1095 value threshold of 1e-3 (Conesa *et al.*, 2005). Blast2GO was also used to
1096 search through the NR database and assign Gene Ontology (GO) terms for all
1097 differentially expressed transcripts. GO biological processes were also
1098 assigned to each transcript through manually searching the Uniprot database.

1099

1100 We found a total of 138 differentially expressed candidate transcripts that
1101 were differentially expressed with a log-fold change of >4 between
1102 populations ($P < 0.01$). The significance of differences in expression of these
1103 transcripts was confirmed by the Benjamini and Hochberg FDR corrections
1104 ($FDR < 0.01$). Of these, 103 showed high similarity to known vertebrate
1105 homologues or hypothetical protein sequences in other species (*E*-value cut-
1106 off of 1e-3; Table S7). The remaining 35 transcripts were not successfully
1107 matched to known protein sequences.

1108

1109 The aim of our study was to test whether there is differential expression of
1110 genes directly linked to the response to infection between populations.

1111 Previous studies have demonstrated that there are energetic costs associated
1112 with immune responses (Bonneaud *et al.*, 2012a), as well as differences in
1113 the expression of immune-associated genes in spleen tissue (Bonneaud *et*
1114 *al.*, 2011, 2012b). Therefore, we further processed these 103 annotated
1115 transcripts by carrying out literature searches to identify 20 specific transcripts
1116 associated with immune function, angiogenesis, autophagy, glucose
1117 metabolism, inflammation, mitochondrial electron transport chain, proteolysis
1118 and stress/damage, to assess underlying differences in response to infection,
1119 attributable to differences in history of pathogen exposure (Table 2).

1120

1121 **Statistical analyses**

1122 All statistical analyses were conducted using RStudio v0.99.902 (R Studio
1123 team, 2017). Six individuals exhibited vastly higher antibody concentration at
1124 day 14 and 28, and deviated drastically from other individuals. Analyses were
1125 first run including those individuals and secondly with excluding them as
1126 outliers. Significance of results did not differ after their removal, so they were
1127 excluded from the data set for all analyses, leaving 44 individuals. General
1128 linear mixed effect models (Gaussian family, lme4 package) were used to
1129 investigate the effect of population of origin and days post inoculation (dpi) on
1130 antibody concentration (Table S1). Bacterial isolate ID and year of
1131 *M.gallisepticum* isolate were controlled for as random effect terms. We then
1132 tested for interactions between antibody concentrations at specific time points
1133 between populations using paired t-tests, with a significance level of 0.05.

1134

1135 To assess if circulating IgY was associated with symptom severity, we
1136 removed individuals who did not develop symptoms (n=6). We then used a
1137 linear regression with mean quantitative conjunctival score as the response
1138 variable and host IgY concentration at 14, 28 and 35 dpi as the explanatory
1139 terms.

1140 Second, we investigated the effect of host IgY concentration on the probability
1141 of developing clinical symptoms that would be lethal in the wild using a logistic
1142 regression with mortality as the response term and host IgY concentration at
1143 14, 28 and 35 dpi as the explanatory terms. Next, the relationship between
1144 host IgY and pathogen clearance was examined using logistic regression with
1145 clearance as a response variable and host IgY concentration at 14 and 28 as
1146 explanatory terms. Clearance was defined using qualitative symptom scoring,
1147 which was measured until day 34. We therefore excluded antibody
1148 concentration at 35dpi from our clearance models. Logistic regression was
1149 also used to test the association between the response term clearance and
1150 the explanatory terms host IgY concentration at 14 and 28. Measurements of
1151 symptom score (and therefore host recovery) were taken until 34 dpi, and so
1152 antibody concentration at 35dpi was excluded from the analyses. For all
1153 models with a single explanatory term significance was determined by
1154 comparing the MAM with the null model (which only contained the response
1155 variable) using ANOVA.

1156

1157

1158

1159

1160 **Results**

1161 **Antibody Response**

1162 **1. Population differences in concentration of systemic IgY**

1163


1164 To identify whether an increased humoral response had accompanied the
1165 evolution of resistance in coevolved house finch populations, we compared
1166 systemic IgY concentration between individuals originating from coevolved
1167 and unexposed populations at 14, 28 and 35 days post inoculation (dpi).
1168 Alabama birds mounted a higher antibody response over the course of
1169 infection than Arizona birds (GLM, estimate=0.01, $X^2=8.99$, $p<0.01$, Table
1170 S1). However, this population difference was due to differences in antibody
1171 production at day 14 only (14 dpi: paired t-test, $T_{19}= 2.15$, $P=0.04$; 28 dpi:
1172 paired t-test, $T_{19}= -0.83$, $P= 0.42$; 35 dpi: paired t-test, $T_{19}= -1.72$, $P= 0.10$).

1173

1174

1175

1176



1177

1178 **Figure 1. Systemic antibody (IgY) concentration in finches from**
 1179 **coevolved, Alabama (blue) and unexposed, Arizona populations (red) at**
 1180 **14, 28 and 35 dpi. Populations differ significantly in their early IgY responses**
 1181 **two weeks post inoculation.**

1182

1183

1184 **2. Protective benefits of IgY**

1185

1186 Mean symptom severity was not associated with circulating antibody
 1187 concentration at day 14 ($R^2 = 0.01688$, $t_{42} = -0.849$, $P = 0.4005$; $Y = 72.63 -$
 1188 $15.11X$), day 28 ($R^2 = 0.0006128$, $t_{42} = -0.16$, $P = 0.8733$; $Y = 48.744 - 1.808X$)
 1189 or day 35 ($R^2 = 0.06568$, $t_{42} = 1.718$, $P = 0.0931$; $Y = 0.3712 + 23.3488 X$),
 1190 indicating that antibody levels had no significant relationship with infection
 1191 associated damage to host conjunctival tissues. Similarly, we found no
 1192 significant association between antibody concentration at day 14 (logistic
 1193 regression: $Z = -1.534$, $df = 42$, $p = 0.1128$), 28 (logistic regression: $Z = 0.557$,

1194 df=42, p= 0.5753) or 35 (logistic regression: Z= 1.192, df=42, p= 0.2248) on
1195 the probability of host death, suggesting that antibody concentration had no
1196 relationship with the log likelihood of infection induced mortality. Furthermore,
1197 we found no significant association between IgY levels at days 14 (logistic
1198 regression: Z= 1.469, df=40, p= 0.1245) or 28 (logistic regression: Z= 0.228,
1199 df=40, p= 0.8206) and the probability of recovery from symptoms. Finally,
1200 antibody concentration was not a significant predictor of the probability of
1201 pathogen clearance (IgY day 14: logistic regression: Z= 0.215, df=42,
1202 p=0.8305; IgY day 28: logistic regression: Z= -0.800, df=42, p= 0.4007),
1203 which indicates that antibody levels had no significant relationship with the
1204 probability of clearing infection.

1205


1206 **Population differences in gene expression**

1207

1208 The gene expression profile of birds from the unexposed population (Arizona)
1209 was characterised by the up-regulation of genes involved with innate immunity
1210 (Akrin-2 isoform X1, Lysophosphatidylcholine acyltransferase 1 and Sorting
1211 nexin-3 isoform X1); glucose metabolism via the insulin receptor pathway
1212 (Insulin receptor substrate 4 and Phosphatidylinositol 4,5-bisphosphate 3-
1213 kinase catalytic subunit alpha isoform); inflammation (Cyclin-dependent
1214 kinase 19 like); proteolysis (Mast-cell protease 1A-like and Dipeptidyl
1215 peptidase 2 isoform X3) and response to damage/stress (DNA-polymerase
1216 kappa isoform X1). However, the gene expression profile of birds originating
1217 from the coevolved population (Alabama) was characterised by the up-
1218 regulation of genes associated with adaptive immunity (AP-1 complex subunit

1219 gamma-1; inflammation (NF-kappa-B-activating protein); angiogenesis
 1220 (Heparanase-isoform X2); autophagy (Myotubularin-related protein 8 and
 1221 Autophagy-related protein 9A) and the mitochondrial electron transport chain
 1222 (Dynamin-1-like protein isoform X4; Calcium uptake protein 2, mitochondrial
 1223 isoform X2 and NADH dehydrogenase [ubiquinone] flavoprotein 3,
 1224 mitochondrial; Table 2, Figure 3).

1225



1226

1227

1228 **Figure 2. Log fold difference in transcript expression.** Subset of
 1229 transcripts associated with adaptive immunity (AD; N=1); angiogenesis (N=1);
 1230 autophagy (AU; N=2); glucose metabolism (GM; N=2); immunity (I; N=1);
 1231 innate immunity (IN; N=2); inflammation (INF; N=5); mitochondrial electron
 1232 transport chain (M; N=3); proteolysis (P; N=2) and stress/damage (S; N=1).
 1233 Negative values represent higher expression in Arizona birds relative to
 1234 Alabama and positive values represent higher expression in Alabama relative
 1235 to Arizona. Abbreviations were assigned to correspond with grouping by
 1236 function (Table 2).

Table 2. Differentially expressed transcripts between unexposed and coevolved finch populations

Vertebrate Homologue	LFC	Abbreviation	GO Biological Process	Grouping
AP-1 complex subunit gamma-1	9.92	AD1	Antigen processing and presentation of exogenous peptide antigen via MHC class II	Adaptive immune response
Heparanase isoform X2	7.75	AN1	Angiogenesis involved in wound healing	Angiogenesis
NF-kappa-B-activating protein	9.61	INF5	T cell differentiation in thymus	Adaptive immune response
Myotubularin-related protein 8	11.22	AU1	Negative regulation of autophagy	Autophagy
Autophagy-related protein 9A	4.53	AU2	Autophagosome assembly	Autophagy
Insulin receptor substrate 4	14.83	GM1	Insulin receptor signalling pathway	Glucose metabolism
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	9.40	GM2	Insulin receptor substrate binding	Glucose metabolism
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3	7.86	I1	Immune response	Immune associated
Akirin-2 isoform X1	9.83	INF4	Innate immune response	Innate immune response
Lysophosphatidylcholine acyltransferase 1	8.27	IN2	Neutrophil degranulation	Innate immune response
Sorting nexin-3 isoform X1	10.67	IN3	Intralumenal vesicle formation	Innate immune response
Cyclin-dependent kinase19-like	11.69	INF1	Positive regulation of inflammatory response	Inflammation
Dynamin-1-like protein isoform X4	8.10	M1	Mitochondrion organization	Mitochondrial
Calcium uptake protein 2, mitochondrial isoform X2	10.94	M2	Mitochondrial calcium ion homeostasis	Mitochondrial
NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial	9.19	M3	Mitochondrial ATP synthesis coupled electron transport	Mitochondrial
Mast cell protease 1A-like	10.85	P1	Proteolysis	Proteolysis
Dipeptidyl peptidase 2 isoform X3	8.94	P2	Proteolysis	Proteolysis
DNA polymerase kappa isoform X1	11.62	S1	Cellular response to DNA damage stimulus	Stress
Tyrosine-protein kinase Fer-like	8.39	INF2	Actin cytoskeleton reorganization	Immune associated
E3 UFM1-protein ligase 1	9.20	INF3	Negative regulation of apoptotic process	Immune associated

A subset (N=19) of the successfully annotated, differentially expressed isoforms (N=103) in Alabama (bold) and Arizona, chosen for their relation to immunity; inflammation; mitochondrial electron transport chain; proteolysis; stress; glucose metabolism and angiogenesis. For full details of differentially expressed isoforms see Supplementary Table 1.

1741 **Discussion**

1742 Many parasites, including *M.gallisepticum* are capable of manipulating host
1743 immune responses. This means that assessing which components of host
1744 immune responses are protective can be complex. Here, we demonstrate that
1745 finches from coevolved populations show higher systemic IgY concentration
1746 relative to those from unexposed populations at 2 weeks post infection, but
1747 that IgY concentration has no clear relationship with host recovery, mortality
1748 or clearance of *M.gallisepticum*. Transcriptional profiles of both populations
1749 revealed stark inter-population differences, with finches originating from
1750 unexposed populations exhibiting greater expression of transcripts that relate
1751 to inflammation and innate immune processes relative to those from
1752 coevolved populations, who overall, showed enhanced adaptive immunity.
1753 Furthermore, our results suggest that coevolved birds do not benefit from
1754 protection through increased antibody response, and exhibit the potential to
1755 avoid immune manipulation by the pathogen.

1756

1757 Our results suggest that antibody concentration is significantly higher in
1758 finches originating from Alabama at 14 dpi. However, we were unable to find a
1759 link between IgY concentration and recovery, mortality and pathogen
1760 clearance. This may be attributable to the fact that we know relatively little
1761 about the role of IgY in pathogen control. IgY is understood to be the
1762 functional equivalent of mammalian IgG, which (among its versatile roles) is
1763 involved in antigen detection, although little is known about its role in
1764 activating complement pathways (Warr *et al.*, 1995). Previous studies in
1765 poultry have found no evidence for a protective role of IgY against

1766 *M.gallisepticum* infection (Noormohammadi *et al.*, 2002). However, three
1767 independent studies of *M.gallisepticum* infection in chickens have suggested
1768 a primary role for the local secretory antibody, IgA in controlling
1769 *M.gallisepticum* infection through the prevention of bacterial establishment in
1770 mucosal cells at the site of infection (Yagihashi *et al.*, 1987, 1992; Avakiana &
1771 Leyb, 1993). However, given the tractability of taking haematological samples
1772 relative to tracheal washings in live birds, systemic IgY was examined here as
1773 an effective measure of the level host resistance through investigating its
1774 efficacy.

1775

1776 One reason for inter-population differences in antibody response may be that
1777 higher circulating antibody titres arise a result of increased activation of the
1778 other innate/acquired processes that are effective for protection. In
1779 concordance with results from a previous experimental infection of birds from
1780 the same populations (Bonneaud *et al.*, 2012b), we found transcriptional
1781 differences between populations in genes related to both innate and acquired
1782 immune components. Antibodies are generated by the action of the adaptive
1783 immune system, and therefore it is entirely plausible that heightened antibody
1784 concentration may be related to proliferation of B-lymphocytes in response to
1785 infection. It is also important to note that much of the variation in host immune
1786 phenotype is likely influenced by pathogen genotype x host genotype
1787 interactions (Lazzaro & Little, 2009). Indeed, house finches are continually
1788 adapting to *M.gallisepticum*, and therefore it is unlikely that their response to
1789 infection is optimally adapted at any one point in time.

1790

1791 One of the key mechanisms for pathogen clearance in vertebrate immunity is
1792 the inflammatory response (Ashley *et al.*, 2012). Dysregulation of this
1793 response can be damaging to host tissues (referred to as autoimmunity) or at
1794 worst, fatal (Warrington *et al.*, 2011; Wiersinga *et al.*, 2014). Recent studies in
1795 house finches have shown that the pathogenicity of *M.gallisepticum* involves
1796 the promotion of pro-inflammatory cytokines at the early stages of infection (3-
1797 6 dpi) (Vinkler *et al.*, 2018). Here we show that genes associated with
1798 promoting and regulating inflammation were highly expressed in Arizona
1799 finches. First, cyclin dependent kinase 19-like (INF1) was up regulated in
1800 finches from Arizona, relative to birds from Alabama. Cyclin dependent
1801 kinases (CDKs), are part of the pro-inflammatory response and expression of
1802 the components of the CDK/cyclin system are regulated by the NF κ β (nuclear
1803 factor κ β) transcription factors (Schmitz & Kracht, 2016). In addition, three
1804 other genes: Tyrosine-protein kinase Fer-like (INF2); E3 UFM1-protein ligase
1805 1 (INF3) and Akirin-2 isoform X1 (INF4) were also more highly expressed in
1806 Arizona finches relative to Alabama. INF2 acts downstream of EGFR to
1807 promote activation of NF κ β and cell proliferation (Tsygankov, 2003), INF3 is
1808 thought to be involved with modulating NF κ β signalling (Li *et al.*, 2017), and
1809 INF4 is necessary for the expression of a subset of NF κ β genes, as well as
1810 IL-6 production (Ghosh & Hayden, 2008).

1811

1812 In finches from coevolved populations, we find only one gene with a potential
1813 link to inflammation: NF κ β activating protein (INF5), which induces pro-
1814 inflammatory NF κ β transcription factors (Baeuerle & Henkel, 1994). Evidence
1815 of a pro-inflammatory response in coevolved finches is consistent with recent

1816 results from Vinkler and colleagues, who demonstrate strong pro-
1817 inflammatory responses in coevolved birds originating from Virginia in
1818 response to a post-resistance isolate of *M.gallisepticum* (Vinkler *et al.*, 2018).
1819 However, as birds originating from unexposed populations appear to show
1820 heightened expression of a higher number of genes relating to inflammation
1821 compared with those from coevolved populations, this may be indicative that
1822 coevolved birds have developed an enhanced ability to decrease their
1823 inflammatory responses to *M.gallisepticum*, which could protect individuals
1824 from immune manipulation by the pathogen.

1825

1826 Along side the potential for avoidance of immune-manipulation, finches from
1827 Alabama also appear to show enhanced adaptive immunity. Here, we show
1828 that finches originating from Alabama up-regulate AP-1 complex subunit
1829 gamma-1, which is associated with antigen presentation via MHC class II
1830 (Hiltbold & Roche, 2002). The major histocompatibility complex (MHC) is a
1831 component of the acquired immune response, involved in pathogen
1832 recognition. The role of MHC molecules is to bind to foreign antigens and
1833 present them on cell surfaces for recognition by T cells (Janeway *et al.*, 2001).
1834 In chickens, a shift in infiltrating populations of CD4⁺ and CD8⁺ T-cell
1835 receptors associated with MHC recognition has been recorded in response to
1836 infection with *M.gallisepticum* (Gaunson *et al.*, 2000b). In house finches,
1837 increased expression of MHC invariant chain II, which is essential for the
1838 assembly of MHC class II molecules, was also found in finches from Alabama,
1839 with down regulation of this gene in Arizona birds (Bonneaud *et al.*, 2012b),

1840 suggesting that the MHC complex may have been subject to selection during
1841 the evolution of resistance.

1842

1843 Mounting a protective immune response is usually accompanied by some
1844 physiological cost (Boots & Haraguchi, 1999) and it has been known for some
1845 time that the strength of immune responses are dependent on trade offs with
1846 other energy-requiring processes, such as reproduction (Webster &
1847 Woolhouse, 1999). In a previous study, it was shown that finches originating
1848 from Alabama lost significantly more mass relative to those from Arizona in
1849 response to infection, and that these individuals also harbored lower bacterial
1850 loads, and highly expressed immune-related genes (Bonneaud *et al.*, 2012a),
1851 suggesting that infection may give rise to different energetic needs in birds
1852 from coevolved versus unexposed populations. In our study, finches from
1853 Alabama up-regulated three genes involved in the mitochondrial electron
1854 transport chain, and therefore associated with energy expenditure/usage:
1855 Dynamin-1-like protein isoform X4; Calcium uptake protein 2, mitochondrial
1856 isoform X2 and NADH dehydrogenase [ubiquinone] flavoprotein 3. Taken
1857 together, the results of the present study may provide further evidence for a
1858 distinct cost of immunity to *M.gallisepticum*, demonstrating that energy
1859 requirements during infection may differ between populations.

1860

1861 In addition, we were able to find evidence of another inter-population
1862 difference in energy usage that may relate directly either differential costs of
1863 infection, or may represent another mechanism of host manipulation by
1864 *M.gallisepticum*. Finches from unexposed populations showed significant up-

1865 regulation of two genes involved in glucose metabolism via the insulin
1866 transduction pathway: Insulin receptor substrate 4 and Phosphatidylinositol
1867 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, as well as a gene
1868 involved with the stress response: DNA polymerase kappa isoform X1. The
1869 insulin transduction pathway is essential for maintaining glucose homeostasis,
1870 although has many roles including countering inflammation through inhibition
1871 of NF κ B pathways (Dandona *et al.*, 2001). Studies examining physiological
1872 stress, have shown that the stress system and the immune system are
1873 intimately linked (Elenkov *et al.*, 1999), with periods of acute/chronic stress
1874 either boosting or decreasing the immune response respectively and resulting
1875 hypercortisolemia (Dhabhar *et al.*, 2012). Furthermore, as insulin is directly
1876 opposed by the action of cortisol, infection can sometimes lead to
1877 hyperglycemia through hyperinsulinemia or in extreme cases, insulin
1878 resistance (McGuinness, 2005). In the future, an additional comparison with a
1879 non-inoculated individuals is necessary in order to determine whether
1880 Alabama birds in fact down-regulate genes involved with insulin pathways
1881 relative to Arizona birds, in which case, this may purely represent differential
1882 energy usage between populations. Conversely, our results may demonstrate
1883 an interaction between stress and the action of the immune system in
1884 unexposed individuals if these genes are up regulated in Arizona birds only; in
1885 which case, this may indicate that coevolved populations have evolved a
1886 mechanism to avoid this damaging effect.

1887
1888 Through examining immune measures in relation to measures of host health,
1889 as well as using next generation sequencing techniques, we were able to
1890 uncover the lack of protective benefits of IgY, as well as elucidate some of the

1891 other immune components that may confer host survival. A number of
1892 unexplored avenues remain. For example, a more comprehensive
1893 understanding of the pathogenesis and virulence factors of *M.gallisepticum* in
1894 house finches specifically will enable a more thorough understanding of the
1895 results presented here. In particular, this would help in partitioning which
1896 components of the immune system are host and pathogen driven.
1897 Furthermore, comparisons of responses to infection at additional time points
1898 during infection (for example in the early stages) and their relationship with
1899 host fitness are needed to further explore in detail, the adaptive significance of
1900 immune measures.

1901

1902

1903

1904

1905

1906

1907


1908

1909

1910

1911

1913




1914
1915

1916 **Figure S1. Flow diagram of the 2 strain - 2 phenotype SIR model.** Model
1917 illustration showing the flow of movements of individuals in the population
1918 ($N_s + N_r$) subdivided into ($N_s = S_s + I_s^l + I_s^h + R_s$) and ($N_r = S_r + I_r^l +$
1919 $I_r^h + R_r$) where $b(t)$ is the seasonal birth rate, $\beta(t)$ is the seasonal
1920 transmission coefficient, σ is the recovery rate, ζ is the disease-associated
1921 mortality rate, and $\mu(t)$ is the natural and season-dependent death rate.


1922

1923
1924



1925
1926
1927
1928
1929
1930
1931
1932
1933

Figure S2. Seasonal variation in birth, death and disease transmission. (a) Seasonal variation in birth rate, $b(t, b_0, k_b)$, with peaks in mid-summer. (b) Seasonal variation in mortality rate, $\mu(t, \mu_0, k_d)$. (c) Semi-annual variation in disease transmission rate, $\beta(t, \beta_0, k_t)$. Parameter values as in Table 1 (main text).



1935

1936

Figure S3. Stratified prevalence of *M.gallisepticum*. Timeseries showing

infection prevalence in each of the four host classes: I_{nr}^l (black), I_{nr}^h (blue), I_r^l

(red) and I_r^h (green). Initially, prevalence is highest in I_{nr}^l (susceptible hosts

infected with low virulence *Mg*) because high rates of mortality in susceptible

birds (initially the most common host genotype) put high virulence strains at a

disadvantage. However, as the prevalence of the resistant host phenotype

increases, prevalence of the high virulence bacterial strain increases, as


carrying the resistance trait reduces the overall fitness costs imposed by the

bacteria and thus allows for the evolution towards higher levels of virulence.

Parameter values: $\rho_1 = 1, \rho_2 = 1, \rho_3 = 0.1, \lambda_3 = 2$; other parameter values as

in Table 1 (main text).

1947




1948
1949

1950 **Figure S4. The effects of the recovery rate on the selection of host**
 1951 **resistance and bacterial virulence.** (a) Relative prevalence of the resistance
 1952 host phenotype 10 years post emergence. Increasing the rate at which birds
 1953 recover from infection leads to slower selection of resistance due to the
 1954 overall reduction in infection prevalence and hence selection pressure. (b)
 1955 Timeseries showing the relative frequency of the high virulence *Mg* strain.
 1956 With an increase in the recovery rate and therefore decrease in selection
 1957 pressure, there is a reduction in the rate of host phenotypic change, leading to
 1958 decrease in the rate at which the more virulent bacterial strain becomes
 1959 dominant. Parameter values: (a) $\lambda_3 = 2$; (b) $\lambda_3 = 2, \rho_1 = 1, \rho_3 = 0.1$; other
 1960 parameter values as in Table 1 (main text).

1961

1962



1963

1964

1965

1966

1967

1968

1969

1970

1971

1972

1973

1974

1975

1976

1977


1978

1979

Figure S5: The effect of relative susceptibility on the selection of host resistance and bacterial virulence. (a) Following disease emergence, there is a significant decrease in the number of susceptible (solid line) and total number of hosts (dashed line) in the population over time. (b) Number of individuals infected with the low virulence (solid line) and high virulence strain (dashed line) over time showing initial dominance of the low virulent strain, which eventually gets outcompeted. (c) Change in the proportion of the host population with a non-resistant or resistant phenotype (N_{nr} and N_r , respectively). (d) Proportion of host population infected with low or high virulence strains over time showing an initial expansion of the low virulence strain until the number of resistant hosts has reached a critical threshold that tips the balance in favour of the more virulent strain. Parameter values: $\rho_1 = 0.18, \lambda_3 = 1.3$; other parameter values as in Table 1 (main text). (e) Relative prevalence of the resistance host phenotype 10 years post emergence. Decreasing susceptibility results in slower selection of host

1980 resistance due to the decrease in overall infection prevalence and selection
 1981 pressure. (f) Relative prevalence of the virulent bacterial strain 10 years post
 1982 emergence. High levels of disease-induced mortality rates will select for
 1983 decreased virulence regardless of susceptibility to infection. Yellow circles
 1984 indicate parameter values used in (a)-(d).

1985




1986

1987 **Figure S6. The effect of parasite clearance on the selection of host**
 1988 **resistance and bacterial virulence.** (a) Following disease emergence, there
 1989 is a significant decrease in the number of susceptible (solid line) and total
 1990 number of hosts (dashed line) in the population over time. (b) Number of
 1991 individuals infected with the low virulence (solid line) and high virulence
 1992 strain (dashed line) over time showing initial dominance of the low virulent
 1993 strain, which eventually gets outcompeted. (c) Change in the proportion of
 1994 the host population with a non-resistant or resistant phenotype (N_{nr} and N_r ,
 1995 respectively). (d) Proportion of host population infected with low or high

1996 virulence strains over time showing an initial expansion of the low virulence
 1997 strain until the number of resistant hosts has reached a critical threshold that
 1998 tips the balance in favour of the more virulent strain. Parameter values:
 1999 $\rho_2 = 3, \lambda_3 = 1.4$; other parameter values as in Table 1 (main text). (e) Relative
 2000 prevalence of the resistance host phenotype 10 years post emergence.
 2001 Increasing the rate at which hosts recover from infection leads to slower
 2002 selection of resistance due to the overall reduction in infection prevalence and
 2003 hence selection pressure. (f) Relative prevalence of the virulent bacterial
 2004 strain 10 years post emergence. Increasing the rate at which hosts recover
 2005 from infection still results in the more virulent pathogen dominating
 2006 transmission after ten years, as infection associated death is not so high that
 2007 the pathogen's transmission is impeded. Yellow circles indicate parameter
 2008 values used in (a)-(d).

2009



2010

2011 **Figure S7: RSEM correlation matrix of sample similarity.** Stark differences
 2012 are shown in the transcriptional profiles between Alabama and Arizona
 2013 individuals. Similarity decreases by colour scale, with yellow representing
 2014 100% similarity

1766
1767

Table S1: Differentially expressed transcripts between Alabama and Arizona finches.

Vertebrate Homologue	LFC	GO Biological Process	Species
Insulin receptor substrate 4	-14.83	insulin receptor signaling pathway	<i>Zonotrichia albicollis</i>
WD repeat-containing protein 81 isoform X1	-14.23	aggrephagy	<i>Serinus canaria</i>
Probable ATP-dependent RNA helicase DDX17 isoform X2	-13.43	androgen receptor signaling pathway	<i>Falco peregrinus</i>
Basic leucine zipper and W2 domain-containing protein 1	-12.11	regulation of transcription, DNA-templated	<i>Serinus canaria</i> / <i>Taeniopygia guttata</i> / <i>Zonotrichia albicollis</i>
Putative spermidine/spermine N1-acetyl transferase 1 variant 4	-11.78	angiogenesis	<i>Taeniopygia guttata</i>
Cyclin-dependent kinase 19-like, partial	-11.69	positive regulation of inflammatory response	<i>Cariama cristata</i>
DNA polymerase kappa isoform X1	-11.62	cellular response to DNA damage stimulus	<i>Serinus canaria</i>
DNA-binding protein RFX7 isoform X2	-11.61	regulation of transcription from RNA polymerase II promoter	<i>Parus major</i>
Cullin-4B	-11.52	cell cycle	<i>Apaloderma vittatum</i>
Muscleblind-like protein 1 isoform X14	-11.48	myoblast differentiation	<i>Serinus canaria</i>
Golgin subfamily B member 1 isoform X1	-11.41	ER to Golgi vesicle-mediated transport	<i>Serinus canaria</i>
WD repeat-containing protein 81 isoform X1	-11.05	aggrephagy	<i>Serinus canaria</i>
Mast cell protease 1A-like	-10.85	proteolysis	<i>Serinus canaria</i>
Hypothetical protein AV530_004877	-10.84	unknown	
Nesprin-3 isoform X4	-10.67	cytoskeletal anchoring at nuclear membrane	<i>Serinus canaria</i>
Sorting nexin-3 isoform X1	-10.67	intraluminal vesicle formation	<i>Ficedula albicollis</i>
Eukaryotic translation initiation factor 5	-10.63	activation of GTPase activity	<i>Serinus canaria</i>
Protein LLP homolog	-10.59	dendrite extension	<i>Corvus brachyrhynchos</i>
Muscleblind-like protein 1	-10.48	myoblast differentiation	<i>Leptonychotes weddellii</i>
Nuclear pore complex protein Nup214 isoform X1	-10.33	intracellular transport of virus	<i>Serinus canaria</i>
F-box only protein 30	-10.22	post-translational protein modification	<i>Serinus canaria</i>
DnaJ homolog subfamily A member 2	-9.95	positive regulation of cell proliferation	<i>Zonotrichia albicollis</i>
Akirin-2 isoform X1	-9.83	innate immune response	<i>Falco peregrinus</i>
Tuberin-like	-9.43	unknown	<i>Melospittacus undulatus</i>
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	-9.39	adaptive immune response	<i>Dasyptis novemcinctus</i>
E3 UFM1-protein ligase 1	-9.19	negative regulation of apoptotic process	<i>Corvus cornix cornix</i>
Putative ATP-dependent RNA helicase DDX5, partial	-9.17	alternative mRNA splicing, via spliceosome	<i>Charadrius vociferus</i>
Hypothetical protein UY3_18385	-9.04	unknown	<i>Chelonia mydas</i>
Cytosolic acyl coenzyme A thioester hydrolase	-9.04	acyl-CoA metabolic process	<i>Fukomys damarensis</i>
Lysine-specific demethylase 3B, partial	-9.02	histone H3-K9 demethylation	<i>Serinus canaria</i>
Dipeptidyl peptidase 2 isoform X3	-8.94	proteolysis	<i>Serinus canaria</i>
Protein FAM172A-like, partial	-8.93	unknown	<i>Haliaeetus albicilla</i>
ATP-dependent RNA helicase SUPV3L1, mitochondrial	-8.93	chromatin maintenance	<i>Aquila chrysaetos canadensis</i>
Transcriptional adapter 1, partial	-8.89	histone H3 acetylation	<i>Haliaeetus albicilla</i>
Mas-related G-protein coupled receptor member A1-like	-8.89	chemosensory behavior	<i>Zonotrichia albicollis</i>
tRNA selenocysteine 1-associated protein 1-like isoform X4	-8.81	selenocysteine incorporation	<i>Zonotrichia albicollis</i>
Peptidase M20 domain-containing protein 2, partial	-8.77	unknown	<i>Geospiza fortis</i>
PHD finger protein 10 isoform X2	-8.70	nervous system development	<i>Pseudopodoces humilis</i>
ATP-dependent RNA helicase DDX42, partial	-8.68	protein localization	<i>Phalacrocorax carbo</i>
Glycogenin-1 isoform X2	-8.64	unknown	<i>Serinus canaria</i>

Protein fantom isoform X6	-8.56	brain development	<i>Serinus canaria</i>
Uncharacterized protein LOC108963215	-8.56	unknown	<i>Serinus canaria</i>
Bcl-2-associated transcription factor 1 isoform X5	-8.46	apoptotic process	<i>Balearica regulorum gibbericeps</i>
Tyrosine-protein kinase Fer-like	-8.38	actin cytoskeleton reorganization	<i>Haliaeetus albicilla</i>
Conserved oligomeric Golgi complex subunit 1	-8.37	ER to Golgi vesicle-mediated transport	<i>Taeniopygia guttata</i>
Sodium channel protein type 5 subunit alpha, partial	-8.32	trial cardiac muscle cell action potential	<i>Leptosomus discolor</i>
Lysophosphatidylcholine acyltransferase 1	-8.27	neutrophil degranulation	<i>Zonotrichia albicollis</i>
Protein phosphatase 1M, partial	-8.21	unknown	<i>Parus major</i>
Apoptotic protease-activating factor 1 isoform X2	-8.16	activation of cysteine-type endopeptidase activity involved in apoptotic process	<i>Sturnus vulgaris</i>
Origin recognition complex subunit 3 isoform X2	-8.15	DNA replication	<i>Serinus canaria</i>
Bcl-2-associated transcription factor 1 isoform X3	-8.06	apoptotic process	<i>Serinus canaria</i>
Protein yippee-like 2	-8.01	unknown	<i>Alligator mississippiensis</i>
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3	-7.86	immune response	<i>Serinus canaria</i>
Fas-activated serine/threonine kinase	-7.47	apoptotic signaling pathway	<i>Sturnus vulgaris</i>
ATP-binding cassette sub-family A member 2 isoform X4	-7.07	unknown	<i>Serinus canaria</i>
Tankyrase-2 isoform X1	-5.57	multicellular organism growth	<i>Parus major</i>
SUN domain-containing ossification factor isoform X3	-3.71	multicellular organism development	<i>Serinus canaria</i>
RNA-binding protein 5	13.44	apoptotic process	<i>Geospiza fortis</i>
BAG family molecular chaperone regulator 5 isoform X1	12.69	Golgi organization	<i>Zonotrichia albicollis</i>
Katanin p60 ATPase-containing subunit A1 isoform X1	12.68	cell cycle	<i>Serinus canaria</i>
Hypothetical protein UY3_18385	12.35	unknown	<i>Chelonia mydas</i>
AFG3-like protein 2	11.95	axonogenesis	<i>Geospiza fortis</i>
Uncharacterized protein LOC108447830	11.77	unknown	<i>Corvus brachyrhynchos</i>
Eukaryotic translation initiation factor 5	11.29	activation of GTPase activity	<i>Serinus canaria</i>
Myotubularin-related protein 8	11.22	negative regulation of autophagy	<i>Serinus canaria</i>
Receptor tyrosine-protein kinase erbB-3 precursor	11.06	cranial nerve development	
Nesprin-1	10.97	cytoskeletal anchoring at nuclear membrane	<i>Serinus canaria</i>
Calcium uptake protein 2, mitochondrial isoform X2	10.94	mitochondrial calcium ion homeostasis	<i>Zonotrichia albicollis</i>
Eukaryotic translation initiation factor 5	10.78	activation of GTPase activity	<i>Serinus canaria</i>
Coiled-coil domain-containing protein 117 isoform X2	10.71	unknown	<i>Sturnus vulgaris</i>
Eukaryotic translation initiation factor 5	10.66	activation of GTPase activity	<i>Serinus canaria</i>
Phosphatase and actin regulator 4 isoform X5	10.59	actin cytoskeleton organization	<i>Serinus canaria</i>
AP-1 complex subunit gamma-1, partial	9.92	antigen processing and presentation of exogenous peptide antigen via MHC class II	<i>Anas platyrhynchos</i>
NF-kappa-B-activating protein	9.61	T cell differentiation in thymus	<i>Aquila chrysaetos canadensis</i>
Transmembrane protein C9orf91 homolog	9.59	unknown	<i>Geospiza fortis</i>
Hypothetical protein Y956_04768, partial	9.58	unknown	<i>Nipponia nippon</i>
Centrosomal protein of 290 kDa isoform X7	9.52	cilium assembly	<i>Serinus canaria</i>
UAP56-interacting factor isoform X2	9.48	mRNA export from nucleus	<i>Parus major</i>
UAP56-interacting factor-like isoform X1	9.22	mRNA export from nucleus	<i>Zonotrichia albicollis</i>
NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial	9.19	mitochondrial ATP synthesis coupled electron transport	<i>Serinus canaria</i>
Probable ATP-dependent RNA helicase DHX40	9.13	mRNA splicing, via spliceosome	<i>Serinus canaria</i>
Phosphatidylinositol transfer protein beta isoform isoform X1	9.12	lipid metabolic process	<i>Zonotrichia albicollis</i>
Serine/threonine-protein kinase PAK 3-like	9.09	axonogenesis	<i>Serinus canaria</i>

Endoplasmic reticulum lectin 1	9.08	ERAD pathway	<i>Serinus canaria</i>
Protein phosphatase Slingshot homolog 1-like, partial	9.07	actin cytoskeleton organization	<i>Gavia stellata</i>
Serine/threonine-protein kinase PAK 3-like	8.87	axonogenesis	<i>Ficedula albicollis</i>
Required for meiotic nuclear division protein 1 homolog isoform X4	8.74	unknown	<i>Serinus canaria</i>
Protein lin-54 homolog isoform X1	8.72	cell cycle	<i>Serinus canaria</i>
Inositol polyphosphate 5-phosphatase OCRL-1 isoform X3	8.67	cilium assembly	<i>Serinus canaria</i>
Hypothetical protein N323_08112, partial	8.63	unknown	<i>Cathartes aura</i>
Endoribonuclease Dicer	8.57	apoptotic DNA fragmentation	<i>Geospiza fortis</i>
Nuclear envelope pore membrane protein POM 121	8.36	intracellular transport of virus	<i>Serinus canaria</i>
Hypothetical protein N301_07267	8.35	unknown	<i>Charadrius vociferus</i>
T-lymphoma invasion and metastasis-inducing protein 2 isoform X4	8.34	G-protein coupled receptor signaling pathway	<i>Taeniopygia guttata</i>
Golgin subfamily A member 4 isoform X6	8.32	Golgi to plasma membrane protein transport	<i>Serinus canaria</i>
Dynamin-1-like protein isoform X4	8.09	cellular response to oxygen-glucose deprivation	<i>Serinus canaria</i>
Heparanase isoform X2	7.75	angiogenesis involved in wound healing	<i>Serinus canaria</i>
Ganglioside-induced differentiation-associated protein 2 isoform X1	7.46	response to retinoic acid	<i>Zonotrichia albicollis</i>
Hypothetical protein N334_14123, partial	6.96	unknown	<i>Pelecanus crispus</i>
CAMP-dependent protein kinase inhibitor alpha	6.89	negative regulation of cAMP-dependent protein kinase activity	<i>Acanthisitta chloris</i>
Phosphatidate cytidyltransferase 2	6.27	CDP-diacylglycerol biosynthetic process	<i>Zonotrichia albicollis</i>
Apoptosis inhibitor 5 isoform	6.03	apoptotic process	<i>Pseudopodoces humilis</i>
Autophagy-related protein 9A	4.53	autophagosome assembly	<i>Serinus canaria</i>

1768

1769 Table shows transcripts with a significance value (FDR) <0.01, p-value <0.01
 1770 and a log fold change >4 (N=103). The functional annotation of each
 1771 predicted differentially expressed protein-coding sequence was performed
 1772 with a BLAST search against the nonredundant (NR) database on NCBI using
 1773 Blast2GO with an *E*-value threshold of 1e-3.

1774

1775

1776

1777

1778

1779

1780

1781

1782

Chapter 4: Thesis Discussion

1783

1784

1785

1786 Through theoretically modeling the dynamical interplay between host
1787 resistance and pathogen virulence, we have revealed specific host traits that
1788 likely led to rapid evolution of both antagonists in just a decade. This work
1789 suggests that host resistance evolved through an imperfect strategy, and
1790 likely through a specific type of quantitative immunity that reduces host
1791 mortality through immune action. Indeed, through previous studies examining
1792 splenic gene expression profiles, we have seen changes in the regulation of
1793 genes involved with immune action accompanying the evolution of resistance
1794 (Bonneaud *et al.*, 2011, 2012b). Subsequently, we tested the efficacy of one
1795 immune mechanism at protecting hosts from morbidity and mortality. We
1796 found no evidence to suggest that circulating antibodies were associated with
1797 an increased likelihood of either pathogen clearance, or recovery from
1798 symptoms. This finding is similar to previous findings in chickens, where a link
1799 between increased IgY and increased pathogen control was never made
1800 (Noormohammadi *et al.*, 2002).

1801

1802 In chapter one, we showed that neither a reduction in host susceptibility to *M.*
1803 *gallisepticum* infections, nor an increase in parasite clearance rates, is
1804 compatible with patterns observed in previous studies (Bonneaud *et al.*, 2011;
1805 Hawley *et al.*, 2013). In fact, model simulations suggest that the impact of
1806 each on infection prevalence would reduce disease-induced selection
1807 pressure to the extent that we would no longer be able to observe shifts in
1808 resistant and virulent host and pathogen phenotypes. Instead, our results

1809 suggest that the rapid, disease-induced selection of host resistance traits
1810 based on reducing infection-associated mortality, for instance through a
1811 lowering of pathogen load, was the key driver for the subsequent increase in
1812 bacterial virulence.

1813

1814 Comparing transcriptional responses of coevolved versus naïve house finches
1815 to infection provided novel insights into the nature of effective immune
1816 mechanisms in this system. Interestingly, finches from Arizona up-regulated
1817 many genes involved in inflammation, where as those from Alabama showed
1818 minimal evidence of an increased inflammatory response. Taken together with
1819 the fact that *M.gallisepticum* is known to potentiate inflammatory responses in
1820 chickens (Ganapathy & Bradbury, 2003), this is indicative that one
1821 mechanism for effective protection from *M.gallisepticum* infection may be to
1822 avoid its immune-manipulation capabilities. This may be effective through
1823 limiting the ability of the pathogen to create more microlesions, therefore
1824 infiltrating epithelial and endothelial tissues. Although this warrants more
1825 investigation, this could provide precursory evidence through which finches
1826 can limit mortality.

1827

1828 Based on evidence presented here regarding an as yet unknown role of
1829 insulin pathways and differential energy usage between populations in
1830 response to infection, many unexplored avenues remain. Arizona finches
1831 exhibited up-regulation of a gene associated with stress, in line with similar
1832 previous findings (Bonneaud *et al.*, 2011). Insulin is directly opposed by the
1833 action of cortisol, and therefore infection can sometimes lead to

1834 hyperglycemia through hyperinsulinemia or in extreme cases, insulin
1835 resistance (McGuinness, 2005). Future comparison with a non-inoculated
1836 individuals will help determine whether Alabama birds in fact down-regulate
1837 genes involved with insulin pathways relative to Arizona birds, in which case,
1838 this may purely represent differential energy usage between populations.
1839 Conversely, our results may demonstrate an interaction between stress and
1840 the action of the immune system in unexposed individuals if these genes are
1841 up regulated in Arizona birds only; in which case, this may indicate that
1842 coevolved populations have evolved a mechanism to avoid this damaging
1843 effect.

1844

1845 In light of knowledge gained here regarding the evolution of host immune
1846 responses, it would now be useful to understand how corresponding pathogen
1847 traits that confer increased virulence have co-evolved during the same time
1848 frame. Further study into how these findings relate to host and pathogen
1849 fitness will also allow us to investigate potential patterns of local adaptations
1850 in this system. Moreover, as we were able to identify specific genes that are
1851 up regulated in response to infection, future studies may specifically test the
1852 efficacy of such response pathways in conferring protection, as we have done
1853 with IgY.

1854

1855 In conclusion, the results presented in this thesis are relevant for other host-
1856 pathogen systems, particularly as a demonstration of the power of host-driven
1857 processes influencing the evolutionary trajectory of host resistance and
1858 pathogen virulence. We know from previous modeling studies that the specific
1859 host trait under selection is hypothesized to have serious implications for

1860 whether pathogens evolve increasing or decreasing virulence in response
1861 (Gandon & Michalakis, 2000; Restif & Koella, 2003). Furthermore, we know
1862 from serial passage experiments that imperfect immunity can result in
1863 increases to pathogen virulence (Mackinnon & Read, 2004). Our study
1864 emphasizes the need to understand directional evolutionary responses when
1865 making decisions about control studies or eradication efforts, because if the
1866 strategy is imperfect, increases in pathogen virulence may undermine any
1867 effort. In addition, we present a rare example of the use of RNA-seq based
1868 transcriptomics to characterize the host transcriptome in response to infection.
1869 RNA-seq based transcriptomics has scarcely been applied to wild systems,
1870 largely due to the inability to control conditions in wild populations and due to
1871 the potential for environmental contamination. To the best of our knowledge,
1872 the use of transcriptomics for comparisons of unexposed and coevolved host
1873 responses has not yet been done in this system. Finally, and as has been
1874 noted elsewhere (Pedersen & Babayan, 2011), immune components are not
1875 always protective under all circumstances, which was demonstrated in
1876 chapter 3. Therefore, when measuring immune responses, future studies
1877 should assess whether they are beneficial in the face of the specific pathogen
1878 of interest as this is likely to affect host evolutionary trajectories.

1879

1880

1881

1882

1883

1884

1885

1886 **Bibliography**

- 1887 Adelman, J.S., Kirkpatrick, L., Grodio, J.L. & Hawley, D.M. 2013. House Finch
1888 Populations Differ in Early Inflammatory Signaling and Pathogen
1889 Tolerance at the Peak of *Mycoplasma gallisepticum* Infection. *Am. Nat.*
1890 **181**: 674–689.
- 1891 Altizer, S., Hochachka, W.M. & Dhondt, A.A. 2004. Seasonal dynamics of
1892 mycoplasmal conjunctivitis in eastern North American house finches. *J.*
1893 *Anim. Ecol.* **73**: 309–322.
- 1894 Amorim, J.H., dos Santos Alves, R.P., Bizerra, R., Araújo Pereira, S., Ramos
1895 Pereira, L., Nascimento Fabris, D.L., *et al.* 2016. Antibodies are not
1896 required to a protective immune response against dengue virus elicited in
1897 a mouse encephalitis model. *Virology* **487**: 41–49. Elsevier.
- 1898 Antonovics, J. & Thrall, P.H. 1994. The cost of resistance and the
1899 maintenance of genetic polymorphism in host-pathogen systems. *Proc R*
1900 *Soc L. B.*
- 1901 Ashley, N.T., Weil, Z.M. & Nelson, R.J. 2012. Inflammation: Mechanisms,
1902 Costs, and Natural Variation. *Annu. Rev. Ecol. Evol. Syst.* **43**: 385–406.
- 1903 Atkinson, C.T., Uzzurum, R.B., Lapointe, D.A., Camp, R.J., Crampton, L.H.,
1904 Foster, J.T., *et al.* 2014. Changing climate and the altitudinal range of
1905 avian malaria in the Hawaiian Islands - An ongoing conservation crisis on
1906 the island of Kaua'i. *Glob. Chang. Biol.* **20**: 2426–2436.
- 1907 Avakiana, A.P. & Leyb, D.H. 1993. Protective Immune Response to
1908 *Mycoplasma gallisepticum* Demonstrated in Respiratory- Tract Washings
1909 from *M. gallisepticum*-Infected Chickens. *Avian Dis.* **37**: 697–705.
- 1910 Baalen, M. V. 1998. Coevolution of recovery ability and virulence. *Proc. R.*

- 1911 *Soc. B Biol. Sci.* **265**: 317–325.
- 1912 Baeuerle, P.A. & Henkel, T. 1994. Function And Activation Of Nf-Kappa-B In
1913 the Immune-System. *Annu. Rev. Immunol.* **12**: 141–179.
- 1914 Berdoy, M., Webster, J.P. & Macdonald, D.W. 2000. Fatal attraction in rats
1915 infected with *Toxoplasma gondii*. *Proc. R. Soc. B* **267**: 1591–1594.
- 1916 Best, A., White, A. & Boots, M. 2014. The coevolutionary implications of host
1917 tolerance. *Evolution (N. Y.)*. **68**: 1426–1435.
- 1918 Best, S.M. & Kerr, P.J. 2000. Coevolution of host and virus: the pathogenesis
1919 of virulent and attenuated strains of myxoma virus in resistant and
1920 susceptible European rabbits. *Virology* **267**: 36–48.
- 1921 Bonneaud, C., Balenger, S.L., Hill, G.E. & Russell, A.F. 2012a. Experimental
1922 evidence for distinct costs of pathogenesis and immunity against a
1923 natural pathogen in a wild bird. *Mol. Ecol.* **21**: 4787–4796.
- 1924 Bonneaud, C., Balenger, S.L., Russell, A.F., Zhang, J., Hill, G.E. & Edwards,
1925 S. V. 2011. Rapid evolution of disease resistance is accompanied by
1926 functional changes in gene expression in a wild bird. *Proc. Natl. Acad.*
1927 *Sci.* **108**: 7866–7871.
- 1928 Bonneaud, C., Balenger, S.L., Zhang, J., Edwards, S. V. & Hill, G.E. 2012b.
1929 Innate immunity and the evolution of resistance to an emerging infectious
1930 disease in a wild bird. *Mol. Ecol.* **21**: 2628–2639.
- 1931 Boots, M. & Bowers, R.G. 2004. The evolution of resistance through costly
1932 acquired immunity. *Proc. Biol. Sci.* **271**: 715–723.
- 1933 Boots, M. & Haraguchi, Y. 1999. The Evolution of Costly Resistance in Host-
1934 Parasite Systems. *Am. Nat.* **153**: 359–370.
- 1935 Buckling, A. & Rainey, P.B. 2002. Antagonistic coevolution between a

1936 bacterium and a bacteriophage. *Proc. Biol. Sci.* **269**: 931–6.

1937 Campbell, L.J., Hammond, S.A., Price, S.J., Sharma, M.D., Garner, T.W.J.,
1938 Birol, I., *et al.* 2018. A novel approach to wildlife transcriptomics provides
1939 evidence of disease-mediated differential expression and changes to the
1940 microbiome of amphibian populations. *Mol. Ecol.* 1413–1427.

1941 Cheatsazan, H., de Almedia, A.P.L.G., Russell, A.F. & Bonneaud, C. 2013.
1942 Experimental evidence for a cost of resistance to the fungal pathogen,
1943 *Batrachochytrium dendrobatidis*, for the palmate newt, *Lissotriton*
1944 *helveticus*. *BMC Ecol.* **13**: 27. BMC Ecology.

1945 Conesa, A., Gotz, S., Garcia-Gomez, J., Terol, J. & Talon, M. 2005.
1946 Blast2GO: a universal tool for annotation, visualization and analysis in
1947 functional genomics research. *Bioinformatics*, doi:
1948 10.1093/bioinformatics/bti610.

1949 Cornet, S., Bichet, C., Larcombe, S., Faivre, B. & Sorci, G. 2014. Impact of
1950 host nutritional status on infection dynamics and parasite virulence in a
1951 bird-malaria system. *J. Anim. Ecol.* **83**: 256–265.

1952 Dandona, P., Aljada, A., Mohanty, P., Ghanim, H., Hamouda, W., Assian, E.,
1953 *et al.* 2001. Insulin inhibits intranuclear nuclear factor kappaB and
1954 stimulates IkappaB in mononuclear cells in obese subjects: evidence for
1955 an anti-inflammatory effect? *J. Clin. Endocrinol. Metab.* **86**: 3257–3265.

1956 de Roode, J.C., Yates, A.J., Altizer, S., Roode, J.C. De, Yates, A.J., Altizer,
1957 S., *et al.* 2008. Virulence-transmission trade-offs and population
1958 divergence in virulence in a naturally occurring butterfly parasite. *Proc.*
1959 *Natl. Acad. Sci. U. S. A.* **105**: 7489–94.

1960 Decaestecker, E., Gaba, S., Raeymaekers, J.A.M., Stoks, R., Van

1961 Kerckhoven, L., Ebert, D., *et al.* 2007. Host–parasite “Red Queen”
1962 dynamics archived in pond sediment. *Nature* **450**: 870–873.

1963 Dhabhar, F., Malarkey, W., Neri, E. & McEwen, B. 2012. Stress induced
1964 redistribution of immune cells - from barracks to boulevards to
1965 battlefields: A tale of three hormones. *Psychoneuroendocrinology* **37**:
1966 1345–1368.

1967 Dhondt, A.A., Altizer, S., Cooch, E.G., Davis, A.K., Dobson, A., Driscoll,
1968 M.J.L., *et al.* 2005. Dynamics of a novel pathogen in an avian host:
1969 Mycoplasmal conjunctivitis in house finches. *Acta Trop.* **94**: 77–93.

1970 Dhondt, A.A., Badyaev, A. V., Dobson, A.P., Hawley, D.M., Driscoll, M.J.L.,
1971 Hochachka, W.M., *et al.* 2006. Dynamics of mycoplasmal conjunctivitis in
1972 the native and introduced range of the host. *Ecohealth* **3**: 95–102.

1973 Diebolder, C.A., Beurskens, F.J., De Jong, R.N., Koning, R.I., Strumane, K.,
1974 Lindorfer, M.A., *et al.* 2014. Complement is activated by IgG hexamers
1975 assembled at the cell surface. *Science (80-)*. **343**: 1260–1263.

1976 Duckworth, R.A., Badyaev, A. V, Farmer, K.L., Hill, G.E., Roberts, S.R.,
1977 Duckworth, R.A., *et al.* 2003. First Case of Mycoplasma gallisepticum
1978 Infection in the Western Range of the House Finch (*Carpodacus*
1979 *mexicanus*). *Auk* **120**: 528–530.

1980 Dumke, R. & Jacobs, E. 2016. Antibody response to Mycoplasma
1981 pneumoniae: Protection of host and influence on outbreaks? *Front.*
1982 *Microbiol.* **7**: 1–7.

1983 Elenkov, I.J., Webster, E.L., Torpy, D.J. & Chrousos, G.P. 1999. Stress,
1984 corticotropin-releasing hormone, glucocorticoids, and the
1985 immune/inflammatory response: Acute and chronic effects.

- 1986 Ewing, E.E., Smart, C.D., Bonierbale, M.W., May, G.D. & Fry, W.E. 2000.
- 1987 Genetic mapping from field tests of qualitative and quantitative resistance
- 1988 to *Phytophthora infestans* in a population derived from *Solanum*
- 1989 *tuberosum* and *Solanum berthaultii*. *Mol. Breed.* 25–36.
- 1990 Farmer, K.L., Hill, G.E. & Roberts, S.R. 2002. Susceptibility of a naive
- 1991 population of house finches to *Mycoplasma gallisepticum*. *J. Wildl. Dis.*
- 1992 **38**: 282–286.
- 1993 Farmer, K.L., Hill, G.E. & Roberts, S.R. 2005. Susceptibility of wild songbirds
- 1994 to the house finch strain of *Mycoplasma gallisepticum*. *J. Wildl. Dis.* **41**:
- 1995 317–325.
- 1996 Fassbinder-Orth, C.A., Wilcoxon, T.E., Tran, T., Boughton, R.K., Fair, J.M.,
- 1997 Hofmeister, E.K., *et al.* 2016. Immunoglobulin detection in wild birds:
- 1998 effectiveness of three secondary anti-avian IgY antibodies in direct
- 1999 ELISAs in 41 avian species. *Methods Ecol. Evol.* **7**: 1174–1181.
- 2000 Fischer, J.R., Stallknecht, D.E., Luttrell, M.P., Dhondt, A.A. & Converse, K.A.
- 2001 1997. Mycoplasmal Conjunctivitis in Wild Songbirds: The Spread of a
- 2002 New Contagious Disease in a Mobile Host Population. *Emerg. Infect. Dis.*
- 2003 **3**: 69–72.
- 2004 Ganapathy, K. & Bradbury, J.M. 2003. Effects of cyclosporin A on the immune
- 2005 responses and pathogenesis of a virulent strain of *Mycoplasma*
- 2006 *gallisepticum* in chickens. *Avian Pathol.* **32**: 495–502.
- 2007 Gandon, S., Baalen, M. Van & Jansen, V. a a. 2002. The Evolution of Parasite
- 2008 Virulence , Superinfection ,. *Am. Nat.* **159**: 658–669.
- 2009 Gandon, S., Mackinnon, M.J., Nee, S. & Read, A.F. 2001. Imperfect vaccines
- 2010 and the evolution of pathogen virulence. *Nature* **414**: 751–6.

2011 Gandon, S. & Michalakis, Y. 2000. Evolution of parasite virulence against
2012 qualitative or quantitative host resistance. *Proc. Biol. Sci.* **267**: 985–990.

2013 García, M., Ikuta, N., Levisohn, S., Kleven, S.H., Ikuta, A.N., Levisohn,
2014 B.C.S., *et al.* 2005. Evaluation and Comparison of Various PCR Methods
2015 for Detection of *Mycoplasma gallisepticum* Infection in Chickens
2016 Evaluation and Comparison of Various PCR Methods for Detection of
2017 *Mycoplasma gallisepticum* Infection in Chickens. **49**: 125–132.

2018 Gaunson, J.E., Philip, C.J., Whithear, K.G. & Browning, G.F. 2000a.
2019 Lymphocytic infiltration in the chicken trachea in response to *Mycoplasma*
2020 *gallisepticum* infection. *Microbiology* **146**: 1223–1229.

2021 Gaunson, J.E., Philip, C.J., Whithear, K.G. & Browning, G.F. 2000b.
2022 Lymphocytic infiltration in the chicken trachea in response to *Mycoplasma*
2023 *gallisepticum* infection. *Microbiology* **146**: 1223–1229.

2024 Gaunson, J.E., Philip, C.J., Whithear, K.G. & Browning, G.F. 2006. The
2025 cellular immune response in the tracheal mucosa to *Mycoplasma*
2026 *gallisepticum* in vaccinated and unvaccinated chickens in the acute and
2027 chronic stages of disease. *Vaccine* **24**: 2627–2633.

2028 Ghosh, S. & Hayden, M.S. 2008. New regulators of NF- κ B in inflammation.
2029 *Nat. Rev. Immunol.* **8**: 837–848.

2030 Grabherr, M.G., Brian J. Haas, Moran Yassour Joshua Z. Levin, Dawn A.
2031 Thompson, Ido Amit, Xian Adiconis, Lin Fan, Raktima Raychowdhury,
2032 Qiandong Zeng, Zehua Chen, Evan Mauceli, Nir Hacohen, Andreas
2033 Gnirke, Nicholas Rhind, Federica di Palma, Bruce W., N. & Friedman,
2034 and A.R. 2013. Trinity: reconstructing a full-length transcriptome without a
2035 genome from RNA-Seq data. *Nat. Biotechnol.* **29**: 644–652.

2036 Gregory, P.G., Evans, J.D., Rinderer, T. & de Guzman, L. 2005. Conditional
2037 immune-gene suppression of honeybees parasitized by Varroa mites. *J.*
2038 *Insect Sci.* **5**: 7.

2039 Griffin, M.P. & Catlla, A.J. 2013. Modeling the Effects of Malaria Preventative
2040 Measures. *SIAM Undergraduate Res. Online* **6**: 208–227.

2041 Hartup, B., Mohammed, H., Kollias, G. & Dhondt, A. 1998. Risk factors
2042 associated with mycoplasmal conjunctivitis in house finches. *J. Wildl. Dis.*
2043 **34**: 281–8.

2044 Hawley, D.M., Briggs, J., Dhondt, A.A. & Lovette, I.J. 2008. Reconciling
2045 molecular signatures across markers: Mitochondrial DNA confirms
2046 founder effect in invasive North American house finches (*Carpodacus*
2047 *mexicanus*). *Conserv. Genet.* **9**: 637–643.

2048 Hawley, D.M., Durant, S.E., Wilson, A.F., Adelman, J.S. & Hopkins, W.A.
2049 2012. Additive metabolic costs of thermoregulation and pathogen
2050 infection. *Funct. Ecol.* **26**: 701–710.

2051 Hawley, D.M., Jennelle, C.S., Sydenstricker, K. V. & Dhondt, A.A. 2007.
2052 Pathogen resistance and immunocompetence covary with social status in
2053 house finches (*Carpodacus mexicanus*). *Funct. Ecol.* **21**: 520–527.

2054 Hawley, D.M., Osnas, E.E., Dobson, A.P., Hochachka, W.M., Ley, D.H. &
2055 Dhondt, A.A. 2013. Parallel Patterns of Increased Virulence in a Recently
2056 Emerged Wildlife Pathogen. *PLoS Biol.* **11**.

2057 Hein, I., Birch, P.R.J., Danan, S., Lefebvre, V., Odeny, D.A., Gebhardt, C., *et*
2058 *al.* 2009. Progress in mapping and cloning qualitative and quantitative
2059 resistance against phytophthora infestans in potato and its wild relatives.
2060 *Potato Res.* **52**: 215–227.

2061 Hiltbold, E. & Roche, P. 2002. Trafficking of MHC class II molecules in the
2062 early secretory pathway. *Curr. Opin. Immunol.* 83–90.

2063 Hochachka, W.M. & Dhondt, A.A. 2000. Density-dependent decline of host
2064 abundance resulting from a new infectious disease. *Proc. Natl. Acad. Sci.*
2065 *U. S. A.* **97**: 5303–5306.

2066 Honaas, L.A., Wafula, E.K., Wickett, N.J., Der, J.P., Zhang, Y., Edger, P.P., *et*
2067 *al.* 2016. Selecting superior de novo transcriptome assemblies: Lessons
2068 learned by leveraging the best plant genome. *PLoS One* **11**: 1–42.

2069 Hosseini, P.R., Dhondt, A. a & Dobson, A. 2004. Seasonality and wildlife
2070 disease: how seasonal birth, aggregation and variation in immunity affect
2071 the dynamics of *Mycoplasma gallisepticum* in house finches. *Proc. Biol.*
2072 *Sci.* **271**: 2569–2577.

2073 Janeway, C.J., Travers, P. & Walport, M. 2001. *Immunobiology: The Immune*
2074 *System in Health and Disease*, 5th ed. Garland Science.

2075 Karlsson, E.K., Kwiatkowski, D.P. & Sabeti, P.C. 2014. Natural selection and
2076 infectious disease in human populations. *Nat. Rev. Genet.* **15**: 379–393.

2077 Kerr, P. & McFadden, G. 2002. Immune responses to myxoma virus. *Viral*
2078 *Immunol.* **15**: 229–46.

2079 Kollias, G. V, Sydenstricker, K. V, Kollias, H.W., Ley, D.H., Hosseini, P.R.,
2080 Connolly, V., *et al.* 2004. Experimental infection of House Finches with
2081 *Mycoplasma gallisepticum*. *J. Wildl. Dis.* **40**: 79–86.

2082 Koskela, T., Puustina, S., Salonen, V. & Mutikainen, P. 2002. Resistance and
2083 Tolerance in a Host Plant-Holoparasitic Plant Interaction : Genetic
2084 Variation and Costs. *Evolution (N. Y.)*. **56**: 899–908.

2085 Lazzaro, B.P. & Little, T.J. 2009. Immunity in a variable world. *Philos. Trans.*

2086 *R. Soc. B Biol. Sci.* **364**: 15–26.

2087 Ley, D.H. 2008. *Mycoplasma gallisepticum Infection* (Y. Saif, ed). Iowa State
2088 Press.

2089 Ley, D.H., Berkhoff, J.E. & McLaren, J.M. 1996. *Mycoplasma gallisepticum*
2090 Isolated from House Finches (*Carpodacus mexicanus*) with
2091 Conjunctivitis. *Am. Assoc. Avian Pathol.* **40**: 480–483.

2092 Ley, D.H., Sheaffer, D.S. & Dhondt, A. a. 2006. Further western spread of
2093 *Mycoplasma gallisepticum* infection of house finches. *J. Wildl. Dis.* **42**:
2094 429–31.

2095 Li, Y.-Y., Zhang, G.-Y., He, J.-P., Zhang, D.-D., Kong, X.-X., Yuan, H.-M., *et*
2096 *al.* 2017. Ufm1 inhibits LPS-induced endothelial cell inflammatory
2097 responses through the NF- κ B signaling pathway. *Int. J. Mol. Med.* 1119–
2098 1126.

2099 Liersch, S. & Schmid-Hempel, P. 1998. Genetic variation within social insect
2100 colonies reduces parasite load. *Proc. Biol. Sci.* **265**: 221–225.

2101 Lips, K.R., Brem, F., Brenes, R., Reeve, J.D., Alford, R.A., Voyles, J., *et al.*
2102 2006. Emerging infectious disease and the loss of biodiversity in a
2103 Neotropical amphibian community. *Proc. Natl. Acad. Sci. U. S. A.* **103**:
2104 3165–70.

2105 Lively, C.M. 1989. Adaptation by a Parasitic Trematode to Local Populations
2106 of Its Snail Host Author. *Soc. Study Evol.* **43**: 1663–1671.

2107 Lively, C.M. & Dybdahl, M.F. 2000. Parasite adaptation to locally common
2108 host genotypes. *Nature* **405**: 679–681.

2109 Luttrell, A.M.P., Fischer, J.R., Stallknecht, D.E. & Kleven, S.H. 1996. Field
2110 Investigation of *Mycoplasma gallisepticum* Infections in House Finches (

2111 *Carpodacus mexicanus*) from Maryland and Georgia. *Avian Dis.* **40**:
2112 335–341.

2113 Luttrell, A.M.P., Stallknecht, D.E., Fischer, J.R., Sewell, C.T. & Kleven, S.H.
2114 1998. Natural *Mycoplasma gallisepticum* Infection in a Captive Flock of
2115 House Finches. *J. Wildl. Dis.* **34**: 289–296.

2116 Mackinnon, M.J. & Read, A.F. 2004. Immunity Promotes Virulence Evolution
2117 in a Malaria Model. *PLoS Biol.* **2**: e230.

2118 Marshall, I.D., Dyce, A.L., Poole, W.E. & Fenner, F. 1955. Studies in the
2119 epidemiology of infectious myxomatosis of rabbits. *J. Hyg. (Lond).* **53**:
2120 12–25.

2121 Mazanec, M.B., Kaetzel, C.S., Lamm, M.E., Fletcher, D. & Nedrud, J.G. 1992.
2122 Intracellular neutralization of virus by immunoglobulin A antibodies. *Proc.*
2123 *Natl. Acad. Sci. U. S. A.* **89**: 6901–6905.

2124 McGuinness, O.P. 2005. Defective Glucose Homeostasis During Infection.
2125 *Annu. Rev. Nutr.* **25**: 9–35.

2126 Meitern, R., Andreson, R. & Hörak, P. 2014. Profile of whole blood gene
2127 expression following immune stimulation in a wild passerine. *BMC*
2128 *Genomics* **15**: 1–10.

2129 Miller, M.R., White, A. & Boots, M. 2005. The evolution of host resistance:
2130 Tolerance and control as distinct strategies. *J. Theor. Biol.* **236**: 198–207.

2131 Miller, M.R., White, A. & Boots, M. 2006. The Evolution of Parasites in
2132 Response to Tolerance in Their Hosts : The Good , the Bad , and
2133 Apparent Commensalism. *Evolution (N. Y).* **60**: 945–956.

2134 Mohammed, J., Frasca, S., Cecchini, K., Rood, D., Nyaoke, A.C., Geary, S.J.,
2135 *et al.* 2007. Chemokine and cytokine gene expression profiles in chickens

2136 inoculated with *Mycoplasma gallisepticum* strains Rlow or GT5. *Vaccine*
2137 **25**: 8611–8621.

2138 Noormohammadi, a H., Jones, J.E., Underwood, G. & Whithear, K.G. 2002.
2139 Poor systemic antibody response after vaccination of commercial broiler
2140 breeders with *Mycoplasma gallisepticum* vaccine ts-11 not associated
2141 with susceptibility to challenge. *Avian Dis.* **46**: 623–628.

2142 Palladino, G., Mozdzanowska, K., Washko, G. & Gerhard, W. 1995. Virus-
2143 neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA
2144 isotypes can cure influenza virus pneumonia in SCID mice. *J. Virol.* **69**:
2145 2075–2081.

2146 Paterson, S., Vogwill, T., Buckling, A., Benmayor, R., Spiers, A.J., Thomson,
2147 N.R., *et al.* 2010. Antagonistic coevolution accelerates molecular
2148 evolution. *Nature* **464**: 275–278.

2149 Pedersen, A.B. & Babayan, S.A. 2011. Wild immunology. *Mol. Ecol.* **20**: 872–
2150 880.

2151 Pedersen, A.B. & Greives, T.J. 2008. The interaction of parasites and
2152 resources cause crashes in a wild mouse population. *J. Anim. Ecol.* **77**:
2153 370–377.

2154 Pounds, J.A., Bustamante, M.R., Coloma, L. a, Consuegra, J. a, Fogden,
2155 M.P.L., Foster, P.N., *et al.* 2006. Widespread amphibian extinctions from
2156 epidemic disease driven by global warming. *Nature* **439**: 161–167.

2157 Ramalingam, J., Vera Cruz, C.M., Kukreja, K., Chittoor, J.M., Wu, J.L., Lee,
2158 S.W., *et al.* 2003. Candidate defense genes from rice, barley, and maize
2159 and their association with qualitative and quantitative resistance in rice.
2160 *Mol. Plant. Microbe. Interact.* **16**: 14–24.

- 2161 Read, A.F. 1994. The evolution of virulence. *Trends Microbiol.* **2**: 73–76.
- 2162 Restif, O. & Koella, J.C. 2003. Shared control of epidemiological traits in a
2163 coevolutionary model of host-parasite interactions. *Am. Nat.* **161**: 827–
2164 836.
- 2165 Roberts, S.R., Nolan, P.M., Lauerman, L.H., Li, L.Q. & Hill, G.E. 2001.
2166 Characterization of the mycoplasmal conjunctivitis epizootic in a house
2167 finch population in the southeastern USA. *J. Wildl. Dis.* **37**: 82–8.
- 2168 Roy, A.B. a, Kirchner, J.W., Url, S. & Roy, B. a. 2000. Evolutionary Dynamics
2169 of Pathogen Resistance and Tolerance. *Evolution (N. Y.)* **54**: 51–63.
- 2170 Sansonetti, P.J. & Di Santo, J.P. 2007. Debugging how Bacteria Manipulate
2171 the Immune Response. *Immunity* **26**: 149–161.
- 2172 Sauer, J., Hines, J., Fallon, J., Pardieck, K. & Ziolkowski, D.J. 2012. The
2173 North American breeding bird survey, results and analysis 1966–2011,
2174 version 12.13.2011: House finch *Carpodacus mexicanus*—BBS summer
2175 distribution map, 2006–2010.
- 2176 Savage, A.E. & Zamudio, K.R. 2016. Adaptive tolerance to a pathogenic
2177 fungus drives major histocompatibility complex evolution in natural
2178 amphibian populations. *Proc. R. Soc. B Biol. Sci.* **283**: 20153115.
- 2179 Schmitz, M.L. & Kracht, M. 2016. Cyclin-Dependent Kinases as Coregulators
2180 of Inflammatory Gene Expression. *Trends Pharmacol. Sci.* **37**: 101–113.
2181 Elsevier Ltd.
- 2182 Sepil, I., Lachish, S., Hinks, A.E. & Sheldon, B.C. 2013. Mhc supertypes
2183 confer both qualitative and quantitative resistance to avian malaria
2184 infections in a wild bird population. *Proc. Biol. Sci.* **280**: 20130134.
- 2185 Sheldon, B.C. & Verhulst, S. 1996. Ecological immunology - costly parasite

2186 defenses and trade-offs in evolutionary ecology. *Trends Ecol. Evol.* **11**:
2187 317–321.

2188 Staley, M. & Bonneaud, C. 2015. Immune responses of wild birds to emerging
2189 infectious diseases. *Parasite Immunol.* **37**: 242–254.

2190 Staley, M., Bonneaud, C., McGraw, K., Vleck, C.M. & Hill, G.. 2017.
2191 Detection of *Mycoplasma gallisepticum* in house finches (*Haemorrhous*
2192 *mexicanus*) from Arizona, USA. *Avian Dis.*

2193 Stevens, D.L., Ma, Y., Salmi, D.B., McIndoo, E., Wallace, R.J. & Bryant, A.E.
2194 2007. Impact of antibiotics on expression of virulence-associated
2195 exotoxin genes in methicillin-sensitive and methicillin-resistant
2196 *Staphylococcus aureus*. *J. Infect. Dis.* **195**: 202–211.

2197 Stipkovits, L. & Kempf, I. 1996. Mycoplasmoses in poultry. *Rev. Sci. Tech.* **15**:
2198 1495–1525.

2199 Teoh, E.P., Kukkaro, P., Teo, E.W., Lim, A.P.C., Tan, T.T., Yip, A., *et al.*
2200 2012. The Structural Basis for Serotype-Specific Neutralization of
2201 Dengue Virus by a Human Antibody. *Sci. Transl. Med.* **4**: 139ra83–
2202 139ra83.

2203 Tsygankov, A.Y. 2003. Non-receptor protein tyrosine kinases. *Front. Biosci.* **8**:
2204 1106.

2205 Videvall, E., Cornwallis, C.K., Palinauskas, V., Valkiunas, G. & Hellgren, O.
2206 2015. The avian transcriptome response to malaria infection. *Mol. Biol.*
2207 *Evol.* **32**: 1255–1267.

2208 Viney, M.E., Riley, E.M. & Buchanan, K.L. 2005. Optimal immune responses:
2209 Immunocompetence revisited. *Trends Ecol. Evol.* **20**: 665–669.

2210 Vinkler, M., Leon, A.E., Kirkpatrick, L., Dalloul, R.A. & Hawley, D.M. 2018.

2211 Differing House Finch Cytokine Expression Responses to Original and
2212 Evolved Isolates of *Mycoplasma gallisepticum*. *Front. Immunol.* **9**: 1–16.

2213 Wallace, J.L., Arfors, K.E. & McKnight, G.W. 1991. A monoclonal antibody
2214 against the CD18 leukocyte adhesion molecule prevents indomethacin-
2215 induced gastric damage in the rabbit. *Gastroenterology* **100**: 878–883.

2216 Wang, Z., Farmer, K., Hill, G.E. & Edwards, S. V. 2006. A cDNA macroarray
2217 approach to parasite-induced gene expression changes in a songbird
2218 host: Genetic response of house finches to experimental infection by
2219 *Mycoplasma gallisepticum*. *Mol. Ecol.* **15**: 1263–1273.

2220 Warr, G.W., Magor, K.E. & Higgins, D.A. 1995. IgY: clues to the origins of
2221 modern antibodies. *Immunol. Today* **16**: 392–398.

2222 Warrington, R., Watson, W., Kim, H.L. & Antonetti, F. 2011. An introduction to
2223 immunology and immunopathology. *Allergy, Asthma Clin. Immunol.* **7**:
2224 S1.

2225 Webster, J.P. & Woolhouse, M.E.J. 1999. Cost of resistance: relationship
2226 between reduced fertility and increased resistance in a snail—
2227 schistosome host—parasite system. *Proc. R. Soc. B Biol. Sci.* **266**: 391.

2228 Wells, T.J., Whitters, D., Sevastyanovich, Y.R., Heath, J.N., Pravin, J.,
2229 Goodall, M., *et al.* 2014. Increased severity of respiratory infections
2230 associated with elevated anti-LPS IgG2 which inhibits serum bactericidal
2231 killing. *J. Exp. Med.* **211**: 1893–1904.

2232 Westerdahl, H., Asghar, M., Hasselquist, D. & Bensch, S. 2012. Quantitative
2233 disease resistance: to better understand parasite-mediated selection on
2234 major histocompatibility complex. *Proc. R. Soc. B Biol. Sci.* **279**: 577–
2235 584.

2236 Wiersinga, W.J., Leopold, S.J., Cranendonk, D.R. & van der Poll, T. 2014.
2237 Host innate immune responses to sepsis. *Virulence* **5**: 36–44.

2238 Yagihashi, T., Nunoya, T., Sannai, S. & Tajima, M. 1992. Comparison of
2239 immunity induced with a *Mycoplasma gallisepticum* bacterin between
2240 high- and low-responder lines of chickens. *Avian Dis.* **36**: 125–133.

2241 Yagihashi, T., Nunoya, T. & Tajima, M. 1987. Immunity Induced with an
2242 Aluminum Hydroxide-Adsorbed *Mycoplasma gallisepticum* Bacterin in
2243 Chickens. *Avian Dis.* **31**: 149–155.

2244

2245

2246